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The impact of perioperative factors on metastatic spread subsequent to 
surgery for primary cancer removal is of rising interest. Several studies show 
that anaesthesia for primary cancer surgery might impact cancer recurrence 
by influencing cell proliferation rate and regulating the expression of specific 
oncogenes like neuroepithelial transforming gene 1 (NET1), which has been 
associated with malignant behaviours and represents a novel prognostic 
marker in human epithelial cancers.  
This project investigates the effects of different concentrations of clinically 
available propofol and sevoflurane formulations on canine mammary tumour 
cell proliferation and on the expression of the NET1 gene in three prospective 
controlled in vitro trials. 
Primary (CIPp) and metastatic (CIPm) canine tubular adenocarcinoma cell 
lines were incubated with sevoflurane (1, 2.5 or 4 mM), propofol (1, 5 or 10 μg 
mL-1) or cell culture medium (control). Proliferation was assessed after 6 hours 
of sevoflurane and 6 - 12 hours of propofol exposures, while NET1 expression 
was evaluated after 6 hours of sevoflurane and 6, 12, 24 and 48 hours of 
propofol exposures.  
After 6 hours of propofol exposure, cell proliferation significantly increased 
in CIPp, while after 12 hours cell proliferation significantly increased in CIPp 
and decreased in CIPm. 
After 6 hours of exposure, propofol significantly augmented NET1 
expression in CIPp, whereas in CIPm the highest propofol concentration 
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significantly reduced gene expression. Propofol significantly decreased gene 
expression after 12 and 24 hours of exposure. No significant differences were 
found in CIPm after 48 hours, while the highest concentration of propofol 
significantly increased gene expression in CIPp after 48 hours.  
Sevoflurane significantly increased cell proliferation in CIPp, while it 
significantly decreased cell proliferation in CIPm. The NET1 gene expression 
was significantly increased in CIPm after exposure to the highest sevoflurane 
concentration. 
In conclusion, exposure to both propofol and sevoflurane mainly 
augmented proliferation in primary cells and diminished proliferation in 
metastatic ones. Conversely, propofol mostly decreased NET1 expression, 
while sevoflurane increased NET1 expression in metastatic cells exposed to 
high concentrations.  
A profound comprehension of the molecular mechanisms underlying cancer 
spread is necessary, however, the much more variable environment in the 
clinical setting makes direct translation from in vitro to in vivo conditions 
difficult. Even though the lack of similar trials in veterinary medicine limits the 
chances for comprehensive comparisons, some promising results were 
observed in our study. Future projects assessing the influence of anaesthetic 
techniques on cancer recurrence are warranted.  
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Malignant mammary tumours are a significant cause of morbidity and mortality 
in dogs. They account for 50 to 70% of cancers affecting female dogs and 
represent one of the most common reason for cancer-related death in this 
population (Vail & MacEwen 2000; Misdorp 2002; Davidson 2003; Sorenmo 
2003; Karayannopoulou & Lafioniatis 2016). Comparably, breast cancer 
represents the most widely diffuse type of cancer in women (Porter 2009; 
Ferlay et al. 2014; Ghoncheh et al. 2016). In both human and canine patients, 
death itself is commonly caused by recurrence and metastasis (Schneider et 
al. 1969; Falkson et al. 1995; Vascellari et al. 2016), with tumour cells 
spreading via the lymphatic or cardiovascular systems towards regional lymph 
nodes, lungs, liver and bones (Kitchell & Loar 1997; Misdorp 2002; Sorenmo 
et al. 2003).  
Surgical removal of the primary tumour is considered to be the most 
effective treatment for both human and canine patients diagnosed with 
malignant mammary tumours (Singletary et al. 2003; Sorenmo 2003; Chia et 
al. 2005; Karayannopoulou & Lafioniatis 2016). Even though other treatments, 
e.g. chemotherapy, hormonal therapy and biological therapy, are available 
(Hortobagyi 1998; Bernard-Marty et al. 2004), they are often less efficacious 
than surgical intervention (Rapiti et al. 2006). Adjuvant postoperative 
chemotherapy is often successfully performed in women affected with breast 
cancer, with the aim of increasing the survival rates (Clarke et al. 2005). 
Conversely, postoperative chemotherapy in canine patients is not routinely 
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used (Sleeckx et al. 2011). More often, chemotherapy is only suggested in 
cases of advanced disease with distant metastases or inoperable primary 
tumours (Karayannopoulou & Lafioniatis 2016).  
Human breast cancers and canine mammary tumours share many features 
(Alvarez 2014; Liu et al. 2014), including histological and clinical similarities 
(Ranieri et al. 2013; Liu et al. 2014), comparable age distribution between 
species and malignancy rates (Queiroga et al. 2011). In women and dogs, 
hormonal exposure (both exogenous and endogenous), tumour size, lymph 
node status and changes in expression of steroid receptors or suppressor 
genes have been identified as important factors influencing tumour 
aggressiveness and tendency for metastasis (Yamagami et al. 1996; Chia et 
al. 2005; Morris et al. 2009; Telli & Sledge 2015). For all of these reasons, in 
the last few years, canine tumours have been suggested as translational 
models of naturally occurring cancers in humans (Alvarez 2014). Based on the 
fact that dogs have a shorter lifespan and consequently canine tumours 
require a shorter time to metastasize, clinical canine patients affected with 
mammary tumours could be adopted as a natural model for the study of 
mammary tumour progression on a shorter time scale. 
The possible influence of perioperative factors on metastatic spread is of 
growing interest, and the role of anaesthetic and analgesic techniques has 
been investigated by recent retrospective studies in human medicine (Forget 
et al. 2010; Snyder & Greenberg 2010; Forget & De Kock 2014). Some drugs, 
such as ketamine and thiopental, have been suggested to facilitate cancer 
spread. For instance, they increased the amount of viable tumour cells found 
post-mortem in rats’ lungs after animals were injected with tumour cells and 
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subjected to anaesthesia with these agents (Melamed et al. 2003). 
Conversely, local anaesthetics and non-steroidal anti-inflammatory drugs 
might decrease cancer spread. They seem to inhibit the invasive ability of 
tumour cells (Mammoto et al. 2002) or to impede prostaglandin secretion by 
neoplastic cells, a cancer cell’s mechanism for evading host cell-mediated 
immunity (Wojtowicz-Praga 2003). The choice of anaesthetic drugs and 
techniques may therefore have a central role in the management of 
oncological patients. Bitches affected with mammary cancer, indeed, may 
undergo anaesthesia not only for surgical procedures, but also for diagnostic 
and medical work-ups, being repeatedly exposed to anaesthetic drugs. Thus, 
an understanding of the effects of anaesthetics on canine tumour progression 
becomes fundamental for improving outcome of oncological veterinary 
patients.  
An essential abnormality resulting in the development of cancer is the 
continual unregulated proliferation of neoplastic cells (Feitelson et al. 2015; 
Keibler et al. 2016). In fact, the study of tumour cell proliferation has been 
indicated as a fundamental component when assessing cancer initiation and 
propagation (Cooper 2000; Adan et al. 2016; Präbst et al. 2017). Previous 
research data are available concerning the effects of anaesthetic agents such 
as  propofol and sevoflurane on cancer recurrence. The agent propofol is one 
of the most commonly used intravenous anaesthetics in veterinary and human 
medicine (Berry 2015). Propofol has been shown to exert anti-cancer 
properties, decreasing the proliferation rate of osteosarcoma cells (Ye et al. 
2014) and inhibiting the proliferation rate of breast cancer cells in vitro 
(Siddiqui et al. 2005; Deegan et al. 2009). Propofol has been demonstrated to 
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increase apoptotic rate in non-small lung carcinoma, colon carcinoma and 
breast cancer human cell lines (Song et al. 2014). Furthermore, propofol has 
been proven to initiate the activation and promote the differentiation of T-
helper cells, fundamental in the host’s defence against tumour progression 
(Wada et al. 2007). Although several reports on propofol’s anti-metastatic 
properties are available, the exact mechanisms through which propofol 
exhibits these activities remain incompletely understood. Conversely, in vitro 
(Ecimovic et al. 2013) and retrospective clinical trials (Wigmore et al. 2016) 
have shown that volatile agents like sevoflurane might have a pro-tumorigenic 
effect, facilitating the development of metastases of many solid tumours 
(Wigmore et al. 2016). However, it is unknown whether propofol or sevoflurane 
could facilitate tumour cell proliferation in canine cell lines.  
In human medicine, interest has risen in exploring the effects of drugs on 
the expression of genes associated with tumour cell migration such as 
neuroepithelial transforming gene 1 (NET1). This represents a Ras 
homologue gene family, member A (RhoA)-specific guanine nucleotide 
exchange factor (GEF) and has a fundamental role in the ability of human 
breast adenocarcinoma cells to migrate and invade (Glicrease et al. 2009). To 
the best of the author’s knowledge, the effects of propofol and sevoflurane on 
the expression of NET1 have not previously been investigated in canine cell 
lines. 
The aim of this project was to evaluate the effects of different concentrations 
of clinically available propofol and sevoflurane formulations on cell 
proliferation and on the expression of NET1 in primary (CIPp) and metastatic 
(CIPm) canine mammary tumour cell lines in vitro. 
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2. REVIEW OF THE LITERATURE 
 
2.1 Canine mammary tumours  
Canine mammary tumours are one of the most common types of cancer, 
representing 50 - 70% of all tumours occurring in bitches (Vail & MacEwen 
2000; Camacho et al. 2014). Data regarding the incidence of canine mammary 
tumours vary due to factors such as study design, geographical location, 
routine in performing ovariohysterectomy and composition of the analysed 
population in terms of age, breed, and body size (Grüntzig et al. 2016). A study 
from the United States found an annual incidence rate of 258 malignant 
mammary tumours per 100 000 intact female dogs (Dorn et al. 1968), while a 
Swedish study based on 80 000 mostly intact female dogs reported 111 both 
benign and malignant mammary tumours per 10 000 dog-years at risk 
(Egenvall et al. 2005). A study based on the Swiss canine cancer registry, 
which includes data from 1955 to 2008 identified adenomas/adenocarcinomas 
as the most common tumour, 55% of which were located in the mammary 
gland (Grüntzig et al. 2015). Data from Genoa, Italy, collected between 1985 
and 2002 showed an incidence rate of 192 mammary tumours per 100, 000 
dog-years, which was the highest for all tumour types (Merlo et al. 2008). 
Several studies have shown that benign and malignant mammary tumours 
are not  completely separate entities, instead being part of a biological and 
histopathological progressive carcinogenesis process with direct similarities to 
human breast cancer (Gilbertson et al. 1983; Benjamin et al. 1999; Sorenmo 
et al. 2009). Canine mammary tumours are a very heterogeneous group of 
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neoplasms showing different hormonal expression, grade of aggressiveness 
and histopathological features. According to the literature, from 40% to 70% 
of canine mammary tumours are malignant, and the simple carcinoma 
represents the most common histological type, followed by mixed and complex 
tumours (Salas et al. 2015; Vascellari et al. 2016).  
 
2.1.1 Pathogenesis and risk factors 
Although tumorigenesis is not fully understood, a correlation between 
dysregulation of growth factors or hormones and the development of canine 
mammary tumours has been indicated. In 2008, Queiroga and colleagues 
showed that progesterone increases endogenous growth hormone production 
stimulating local and systemic insulin-like growth factor 1 secretion. These 
findings suggest that growth hormones act as local growth factors favouring 
the development and maintenance of canine mammary tumours in an 
autocrine manner (Queiroga et al. 2008). In parallel, Klopfleisch and co-
workers (2011) suggested that aberrant expression levels of several functional 
classes of genes (e.g. mediators of apoptosis, deoxyribonucleic acid (DNA) 
repair systems, proto-oncogenes, tumour suppressor genes and cell adhesion 
molecules) hint at the molecular mechanisms underlying the development of 
canine mammary tumours. These genes and the proteins they encode may 
represent new potential therapeutic targets. However, the authors declared 
that although canine mammary tumours are among the most common tumours 
of the dog, their molecular carcinogenesis is far from being understood 
(Klopfleisch et al. 2011). 
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It has been widely accepted that ovariohysterectomy at a young age 
decreases the incidence of mammary cancer dramatically. Schneider and 
colleagues (1969) found that female dogs neutered before the first oestrus 
had an incidence of mammary tumours of 0.5%. The incidence increased to 
8% and 26% if dogs were neutered after the first or the second oestrus, 
respectively. The study showed no differences between female dogs 
ovariohysterectomised after the second oestrus and intact ones (Schneider et 
al. 1969). These findings suggest that the critical carcinogenic effects of 
ovarian hormones on the mammary glands are time-limited and occur mostly 
during pubertal growth and maturation (Sorenmo et al. 2003). In accordance, 
physiological hormonal fluctuations during pregnancy or pseudo-pregnancy, 
usually occurring after a few oestrus cycles, have not been found to increase 
the risk of  canine mammary tumour development (Schneider et al. 1969; 
Taylor et al. 1976).  
A number of studies have investigated the effect of administered hormones, 
such as progestin and oestrogen, under laboratory conditions, with the 
majority of the investigators concluding that steroid hormone treatment 
increases the risk of canine mammary tumour development (Giles et al. 1978; 
Concannon et al. 1981; Selman et al. 1995).  
The risk for developing a mammary tumour greatly increases after 5 years 
of age and reaches its highest point at 9 to 13 years (Schneider et al. 1969; 
Yamagami et al. 1996; Merlo et al. 2008), with older individuals being more 
likely to develop malignant lesions (Sorenmo et al. 2009). The life expectancy 
of different breeds also influences the peak incidence age. Larger breeds, 
having a shorter mean lifespan, have been diagnosed at a younger age than 
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smaller breeds (Egenvall et al. 2005). In general, purebred dogs are more 
likely to develop canine mammary tumours. Within this group, smaller breeds 
have a threefold higher risk than larger ones (Grüntzig et al. 2016). 
 
2.1.2 Histological classification 
The histopathological heterogeneity of canine mammary tumours results in a 
variety of proposed classification systems. Table 1 shows an improved system 
published in 2011 (Goldschmidt et al. 2011) based on two earlier 
classifications from the World Health Organization in 1974 and 1999 (Hampe 
& Misdorp 1974; Misdorp et al. 1999). Simple carcinomas are neoplasms 
originating from a single type of cell (epithelial or myoepithelial), while complex 
carcinomas originate from two different types of cells (epithelial and 
myoepithelial together). Mesenchymal neoplasms arise from mesenchymal 
tissue. 
 
Table 1: Histological classification by Goldschmidt et al. (2011). 
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• carcinoma arising from a complex 
adenoma/mixed tumour 
àthe benign counterpart is still detectable in the 
section 
• carcinoma–complex type 
àthe epithelial component is malignant, and the 
myoepithelium is benign 
• carcinoma and malignant myoepithelioma 
àthe epithelial and myoepithelial components are 
malignant 
• carcinoma–mixed type 
àthe epithelial component is malignant; the 
myoepithelial mesenchymal component is benign; 
and the mesenchymal component is cartilage or 
bone 
• ductal carcinoma 
àmalignant counterpart of ductal adenoma 
• intraductal papillary carcinoma 
àmalignant counterpart of 




NEOPLASMS — SPECIAL TYPES 
 
• squamous cell carcinoma 
• adenosquamous carcinoma 
• mucinous carcinoma 
• lipid-rich (secretory) carcinoma 
• spindle cell carcinoma 
• malignant myoepithelioma 
• squamous cell carcinoma–spindle cell 
variant 
• carcinoma–spindle cell variant 
• inflammatory carcinoma  
 
 
MALIGNANT MESENCHYMAL  
 








• other sarcomas 
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• intraductal papillary adenoma (duct 
papilloma) 
• ductal adenoma (basaloid adenoma) 




• complex adenoma (adenomyoepithelioma) 
• benign mixed tumour 
 
 
HYPERPLASIA / DYSPLASIA 
 
• duct ectasia 
• lobular hyperplasia (adenosis) 
• regular 
• with secretory activity (lactational) 
• with fibrosisàinterlobular fibrous connective 
tissue 
• with atypia 
• epitheliosis 
• papillomatosis 













HYPERPLASIA/DYSPLASIA OF THE 
NIPPLE 
 
• melanosis of the skin of the nipple 
 
 
Criteria for malignancy are histological type, nuclear and cellular 
pleomorphism, mitotic index, occurrence of necrotic areas and invasion of the 
tissues surrounding the tumour or the lymphatic vessels. Malignant canine 
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mammary tumours are more frequently of epithelial origin, with tubular 
carcinomas being the most common ones within this group (Sorenmo 2003; 
Sorenmo et al. 2009). Benign lesions are usually adenomas, lobular 
hyperplasia and benign mixed tumours (Sorenmo et al. 2009). 
Most of the available systems for predicting prognosis are based on a 
method used for human breast cancer by Elston and Ellis (1991). This system 
(Table 2; from Sorenmo et al. 2003) divides the tumours into grade I (low 
score, well-differentiated), grade II (intermediate score, moderately 
differentiated) and grade III (high total score, poorly differentiated), based on 
the morphological criteria shown in Table 3 (Sorenmo et al. 2003).  
 
Table 2: Grading system based on the Elston and Ellis system, adopted for dogs (Sorenmo 
et al. 2003). 
Grade of malignancy 
Total score Grade 
3 – 5 points Grade I (low), well-differentiated 
6 – 7 points Grade II (intermediate), moderately differentiated 
8 – 9 points Grade III (high), poorly differentiated 
 
Table 3: Morphological criteria for the Elston and Ellis grading system for human breast 
cancer, adopted for dogs (Sorenmo et al. 2003).  
Criteria for grade of malignancy 
Tubule formation Nuclear polymorphism Mitotic rate 
(Mitoses/ 10 high power 
fields) 
Tubule formation >75% of the 
specimen à 1 point 
Uniform or regular small nucleus 
and occasional nucleoli à 1 point 
0-9 à 1 point 
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Moderate formation of tubular 
arrangements (10-75% of the 
specimen) admixed with areas of 
solid tumour growth à 2 points 
Moderate degree of variation in 
nuclear size and shape, 
hyperchromatic nucleus, and 
presence of nucleoli (some of 
which can be prominent) à 2 
points 
10-19 à 2 points 
Minimal or no tubule formation 
(<10%) à 3 points 
Marked variation in nuclear size 
and hyperchromatic nucleus, often 
with one or more prominent 
nucleoli à 3 points 
>20 à 3 points 
 
Various studies evaluating the prognostic value of this grading system 
found it to be reliable for canine mammary tumours, increasing the potential 
for canine mammary tumours to be used as a natural model for the study of 
human breast cancer (Misdorp 2002; Karayannopoulou et al. 2005; Clemente 
et al. 2010; Goldschmidt et al. 2011). 
 
2.1.3 Clinical presentation  
Mammary tumours are often found by the owner or are incidental findings 
made during routine physical examination performed by the veterinarian since 
dogs affected with mammary tumours are frequently presented as otherwise 
clinically healthy. The tumours are mostly located in the caudal fourth and fifth 
mammary glands, but they can occur anywhere along the mammary chain 
(Cassali et al. 2014). Over 60% of dogs with mammary tumours have more 
than one lesion, and therefore, thorough palpation of all mammary glands is 
recommended.  
The inflammatory carcinoma is a clinical entity characterized by a very 
inflamed, painful, swollen mass, usually confused with a severe mastitis, with 
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a very high risk of metastasis and a survival time of less than 60 days (Vail & 
MacEwen 2000).  
About 50% of malignant canine mammary tumours exhibit invasion of local 
blood or lymph vessels or have already metastasized at the time of surgery, 
with 16% showing systemic metastasis (Gilbertson et al. 1983; Sorenmo et al. 
2003; Karayannopoulou & Lafioniatis 2016). Non-specific symptoms (e.g. 
lethargy, weight loss and weakness) may be observed in dogs with advanced 
metastatic diseases (Sorenmo 2003). Canine mammary tumours can spread 
via the lymphatic or blood vessel systems to regional and distant lymph nodes 
(Sorenmo et al. 2003). Metastasis to the regional lymph node is an early step 
in cancer recurrence and is usually followed by the development of distant 
metastases, mainly in the lungs, liver and bones (Kitchell & Loar 1997; 
Misdorp 2002). Distant metastases ultimately lead to the death of the dog 
(Misdorp & Hart 1979; Benjamin et al. 1999). 
 
2.1.4 Staging and diagnosis 
A widely used method to determine the clinical stage of canine mammary 
tumours is the modified T (tumour size), N (lymph node status) and M 
(metastasis) classification by Owen (1980) shown in Table 4.  
 
Table 4: TNM (tumour size, lymph node status, metastasis) classification by Owen (1980). 
Staging of canine mammary tumours 
Stage Tumour size Lymph node status Metastasis 
Stage 1 T1<3 cm N0 M0 
Stage 2 T2 3-5 cm N0 M0 
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Stage 3 T3 >5 cm N0 M0 
Stage 4 Any N1 (positive) M0 
Stage 5 Any N0 or N1 M1 (distant metastasis) 
 
Cytology is often used as a diagnostic tool in veterinary oncology, and 
cytological findings correlate well with histopathological diagnosis for 
numerous tumour types such as squamous cell carcinomas, soft tissue 
sarcomas, melanomas, mast cell tumours and osteosarcomas, among others 
(Griffiths et al. 1984; Allen et al. 1986; Stockhaus & Teske 2001; Stockhaus et 
al. 2003; Reinhardt et al. 2005). In women, preoperative cytological evaluation 
of breast cancer is used to determine the presence of malignancy and is 
considered a rapid and minimally invasive alternative to surgical biopsies 
(Cheung et al. 1987; Costa et al. 1993; Ciatto et al. 1997; Orell & Miliauskas 
2005). In dogs, little data are available on the value of cytological examination 
of mammary tumours. The few studies report less favourable accuracy of 
cytological diagnosis for mammary tumours than for other tumour types, with 
lower sensitivity and specificity (Griffiths et al. 1984; Allen et al. 1986; Hellmén 
& Lindgren 1989; Stockhaus & Teske 2001). Reasons for this have been 
assumed to lie, in part, with the heterogeneous composition of mammary 
tumours (Misdorp 1979; Rutteman 2000). However, more recent reports 
describe improved accuracy of cytological examination for the diagnosis of 
mammary tumours (Simeonov & Simeonova 2006a; Simeonov & Simeonova 
2006b; Simeonov & Simeonova 2007), with correlations between cytological 
and histological diagnosis varying between 81% and 93% for malignant and 
benign tumours, respectively (Simon et al. 2009). Nevertheless, since surgery 
remains the treatment of choice, histological evaluation after surgical excision 
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is common in practice and still more accurate than cytology (Allen et al. 1986; 
Cassali et al. 2007).  
Staging should include complete blood count, blood biochemistry, urinalysis 
and three-view radiography of the thoracic cavity (Biller et al. 2016; Gundim et 
al. 2016). Additionally, abdominal ultrasound should be conducted, especially 
if distant metastatic disease is suspected. Computed tomography offers a 
more sensitive alternative for detecting pulmonary metastasis than 
radiography. However, while computed tomography is routinely used in 
human medicine, radiography remains the technique of choice in veterinary 
medicine due to its lower costs and higher availability (Nemanic et al. 2006; 
Otoni et al. 2010; Eberle et al. 2011). 
 
2.1.5 Therapy 
The surgical approach is the treatment of choice. Most studies comparing the 
prognostic effects of different surgical approaches could not find any 
differences between simple lumpectomy, regional mastectomy, mastectomy, 
chain mastectomy and staged bilateral mastectomies as long as all lesions 
were sufficiently removed (Schneider et al. 1969; Misdorp & Hart 1976; 
MacEwen et al. 1985; Yamagami et al. 1996; Chang et al. 2005). However, 
multiple nodules should be treated individually because of their possibly 
different histopathological classification (Benjamin et al. 1999).  
Currently, decisions regarding the surgical approach need to consider all of 
the previously described factors such as location, clinical stage and the 
presence of co-morbidities. Nevertheless, the choice of the surgical approach 
is subjective. Commonly, it is recommended that the surgical excision should 
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entirely remove the tumour mass. In the case of different mammary masses, 
regional or chain mastectomy is then suggested. The surgical excision is 
questionable in the case of inflammatory carcinoma due to the diffuse 
microscopic extension of the disease and the high grade of early metastasis 
(Vail & MacEwen 2000; Yamauchi et al. 2012).  
The benefit of concurrently performing ovariohysterectomy is controversial. 
Most studies have found no difference in survival rates of 
ovariohysterectomized dogs relative to intact dogs (Schneider et al. 1969; 
MacEwen et al. 1985; Yamagami et al. 1996; Philibert et al. 2003). However, 
some studies report survival benefits if ovariohysterectomy is conducted within 
the 2 years preceding tumour surgery and for certain types of canine 
mammary tumours (e.g. complex carcinomas; from Sorenmo et al. 2000; 
Chang et al. 2005). 
Few studies have investigated the efficacy of systemic chemotherapy, 
which remains to be confirmed. The chemotherapeutic drugs traditionally used 
in dogs are 5-fluorouracil and cyclophosphamide (Karayannopoulou et al. 
2001), doxorubicin and docetaxel (Simon et al. 2006) and gemcitabine 
(Marconato et al. 2008), but postoperative benefits in survival time were not 
clear in these studies.  
Hormonal therapy with, for instance, oestrogen receptor antagonists (e.g. 
Tamoxifen), frequently used in humans, has not found an application in the 
veterinary field due to lack of information about molecular expression and high 
medical costs (Karayannopoulou & Lafioniatis 2016).  
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2.1.6 Prognosis 
Tumour size, lymph node involvement and histopathological stage are the 
three most important factors associated with prognosis. Despite being part of 
the TNM staging system, tumour size has been recognized as an independent 
prognostic factor (Misdorp & Hart 1976; Bostock 1986; Yamagami et al. 1996) 
with lesions smaller than 3 cm in diameter having a significantly better 
prognosis compared with larger ones (Gilbertson et al. 1983). Similarly, lymph 
node status has prognostic value on its own (Kurzman & Gilbertson 1986). 
Comparably to human breast cancer, metastasis to the regional lymph node 
is considered to be one of the most relevant prognostic factors in the diagnosis 
of canine mammary tumours (Misdorp & Hart 1976; Fitzgibbons et al. 2000). 
Chang and colleagues (2005) suggested that tumour stage, tumour size and 
ovariohysterectomy status were significant prognostic factors associated with 
2-year survival after surgery in dogs with malignant mammary tumours. 
Further, dogs with tumours ≥ 5 cm in diameter and dogs with tumours present 
for > 6 months prior to surgery had a higher risk of lymph node metastases 
(Chang et al. 2005). 
Histopathological type also influences survival. In general, sarcomas have 
a poorer prognosis than carcinomas, with the exception of inflammatory 
carcinomas. Within carcinomas, malignancy increases from carcinoma in situ, 
to complex carcinoma, to simple carcinoma and to anaplastic carcinoma 
(Misdorp et al. 1999).   
One of the current challenges is to identify molecular tools and relevant 
models that can predict the response and potential resistance to therapies 
(Nguyen et al. 2018). Queiroga and colleagues (2010) investigated the 
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relevance of the expression of cyclooxygenase (COX) 1 and 2 enzymes as 
prognostic values in canine mammary tumours. They evaluated the correlation 
of COX1 and COX2 expression with clinico-pathological elements (i.e. tumour 
size, histological type, necrosis, lymph node metastasis), disease-free survival 
time and overall survival (Queiroga et al. 2010). Subsequently, Nguyen and 
co-workers (2018) described invasive canine mammary tumours using human 
pathological criteria including immunohistochemical markers. The same 
authors tried to validate human pathological criteria as prognostic factors for 
canine patients’ outcome. Clinico-pathological criteria, similar to those of 
human oncology, could therefore predict canine invasive mammary 
carcinomas’ short disease course (Nguyen et al. 2018). In a subsequent 
publication, the same group of researchers reported that the current molecular 
classifications of human breast cancer, used for therapeutic decisions, could 
be applied to dogs. Furthermore, the authors stated that dogs are potent 
valuable spontaneous cancer models to test new therapeutic strategies for 
human breast cancer treatment (Abadie et al. 2018). 
 
2.1.7 Canine mammary tumours as a natural model of human 
breast cancer 
There is growing interest in canine mammary tumours as a natural model for 
human breast cancer. In particular, the canine simple carcinoma has been 
recognized as a potential natural model for human breast cancer due to its 
histological and clinical similarities to the human form of the disease (Ranieri 
et al. 2013; Liu et al. 2014).  
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The high incidence rates of mammary tumours in dogs and dogs’ shorter 
lifespan speak in favour of conducting clinical trials in veterinary medicine 
rather than in human medicine. Age-specific incidence rates rise dramatically 
in women older than 40 years and in dogs older than 5 years, with a peak 
incidence age of 55 - 69 years in women and 9 - 13 years in dogs (Yamagami 
et al. 1996; Merlo et al. 2008; Dewis & Gribbin 2009). Taking the different 
lifespan of both species into account, the age distribution of the disease is 
comparable (Queiroga et al. 2011).  
In both humans and dogs, it has been demonstrated that hormonal 
exposure plays an important role in tumour behaviour, especially in the 
epithelial component. In humans, oestrogen expression, found in 20 - 25% of 
cases, is associated with aggressive tumour behaviour and poor prognosis 
(Telli & Sledge 2015). In veterinary studies, important discrepancies were 
found in these data; the majority of larger and undifferentiated canine 
mammary tumours are less likely to express hormonal receptors, although the 
immunohistochemical methods vary between studies with a lack of 
standardization (Kabir et al. 2017; Silveira et al. 2017).  
Body size as a risk and prognostic factor for human breast cancer is well-
established (Greenberg et al. 1985). In particular, weight loss in early adult 
life, and not weight per se, has been demonstrated to decrease the risk of 
breast cancer diagnosed at an early age (Kotsopoulos et al. 2005). In dogs, 
although not without controversy, juvenile obesity seems to increase the risk 
of canine mammary tumour (Sonnenschein et al. 1991; Pérez-Alenza et al. 
1998). A thin body conformation at 9 - 12 months of age, indeed, was shown 
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to reduce the risk of mammary tumours among neutered dogs by 99%, and 
among entire dogs by 40% (Sonnenschein et al. 1991). 
In both species, tumours of epithelial origin are most commonly found 
(Sorenmo 2003; Weigelt et al. 2008; Akiyama & Horii 2009; Sorenmo et al. 
2009). Carcinomas represent 69% of malignant lesions in dogs (Salas et al. 
2015) and up to 95% of malignant lesions in humans (Vinay et al. 2010). 
Histological grading correlates with prognosis (Karayannopoulou et al. 2005; 
Rakha et al. 2008; Goldschmidt et al. 2011). Tumour size, lymph node status 
and overall TNM stage are important prognostic factors in canine mammary 
tumours and human breast cancers (Misdorp & Hart 1976; Gilbertson et al. 
1983; Shek & Godolphin 1988; Hellmén et al. 1993; Yamagami et al. 1996).  
 
2.2 Effects of perioperative period on cancer 
recurrence 
The role played by anaesthetists in avoiding postoperative surgical site 
infections and in facilitating postoperative healing has been acknowledged 
(Nortcliffe & Buggy 2003; Bentov & Reed 2014). However, the role of the 
anaesthetist in ameliorating long-term outcome after cancer surgery remains 
to be elucidated (Sessler et al. 2008; Forget et al. 2010). Exadaktylos and 
colleagues (2006) proposed an analogy between prolonged healing of the 
surgical site and the development of postoperative metastasis, identifying the 
perioperative period as a critical time for deleterious long-term consequences 
for the patient. The general understanding of the relationship between tumour 
biology and host defences is the basis of the idea that interventions occurring 
 Review of the literature
   
 32 
during the perioperative period will affect long-term cancer patient outcome 
(Schmidt et al. 2008; Milsom et al. 2013).  
 
2.2.1 Cancer metastatic mechanisms 
The likelihood of development of tumour metastasis depends on the 
equilibrium between the metastatic potential of the tumour and the anti-
metastatic defences of the host (Shakhar & Ben-Eliyahu 2003). The so-called 
“seed and soil” hypothesis represents one of the theories that explains how a 
tumour acquires metastatic potential (Fidler 2003). It depicts a gradual 
increment of the primary tumour’s dimensions, during which time the supply 
of nutrients is initially met by mechanisms of diffusion, later requiring 
neovascularization. Angiogenic factors are produced and secreted, and a 
system of capillaries rises from adjacent tissues. Cancer cells subsequently 
invade the host circulation, most commonly through the lymphatic vessels. 
The host immune defences, described below, will destroy most of these cells. 
However, surviving tumour cells will become lodged in the capillaries of distant 
organs, then extravasate, multiply, and eventually build their own blood 
supply, becoming a micrometastasis (Fidler 2003; Langley & Fidler 2011).  
A process called epithelial-to-mesenchymal transition (EMT), first 
documented by Elizabeth Hay (1995), facilitates alterations in cell phenotype, 
which are critical in early embryonic morphogenesis. Epithelial cells are 
immobile, firmly connected to neighbouring cells by junction structures (e.g. 
adherent, tight and gap junctions) and have an apical-basal polarity made 
possible by their connection to the basement membrane. Mesenchymal cells, 
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on the other hand, showing a front end-back end polarity, form only temporary 
contacts with neighbouring cells and have the ability to invade and move 
through the extracellular matrix as individual cells (Hay 1995; Kalluri & 
Weinberg 2009; Heerboth et al. 2015; Brabetzl et al. 2018; Roche 2018).  
The EMT not only occurs during embryonic development, but is also 
involved in tissue repair in the adult organism (Acloque et al. 2009), and, more 
recently, its role has been acknowledged in tumour progression (Trimboli et 
al. 2008; Heerboth et al. 2015). Therefore, a classification into three subtypes 
of EMT has been established: EMT type 1 is involved in implantation, 
embryonic formation and organ development; EMT type 2 is involved in repair 
processes following tissue destruction and chronic inflammation; EMT type 3 
enables epithelial tumour cells to invade and migrate (Kalluri & Weinberg 
2009; Zeisberg & Neilson 2009).  
 
2.2.2 Role of the immune system in cancer recurrence 
Neoplastic cells are the result of an evolving process during which they 
erratically mutate and experience selection. Originally, tumour cells are 
blandly antigenic, provoking almost no response from the immune system. 
This stage has been recognised as a phase of uncontrolled proliferation and 
mutation (Shakhar & Ben-Eliyahu 2003). As mutation progresses further, 
cancer cells become more antigenic. This represents a stage of identification, 
elimination and selection of immune-resistant cells. Finally, the tumour cells 
mature mechanisms to escape from the immune response of the host. The 
outcome and duration of these stages may depend on factors which include 
 Review of the literature
   
 34 
the spatial cancer location, molecular mechanisms involved in transformation 
from normal to transformed cells, and the inherent genetic factors of the 
immune system (Mittal et al. 2014). 
The cardinal host defence against metastatic progression is an intact cell-
mediated immune system (Shakhar & Ben-Eliyahu 2003). Natural killer (NK) 
cells are a subpopulation of lymphocytes that spontaneously recognise and 
destroy neoplastic cells, representing the primary defence against cancer cells 
(Biki et al. 2009). Interleukin (IL)-2 and interferon-γ (IFN-γ) are important 
activators of NK cells (Andersen et al. 1998). Several studies demonstrate a 
counter association between NK cell activity at the time of surgical tumour 
excision and the advancement of metastatic disease (Brittenden et al. 1996).  
It is recognised that the cytotoxic activity of T-cells is another key factor in 
defence against cancer. Indeed, human patients presenting with elevated 
cytotoxicity against their primary lung cancer have been seen to undergo 
complete remission, while none of the patients presenting in the same study 
with low cytotoxicity survived (Uchida et al. 1990).  
The importance of an intact cell-mediated immune system can be shown in 
the context of organ transplant receivers, in which immunosuppressive 
therapy is commonly needed and appears to promote the development of 
metastasis (Penn 1993). Importantly, the primary tumour is not destroyed by 
cell-mediated immunity. Nevertheless, cell-mediated immunity may eradicate 
the “minimal residual disease”, a term used to describe the cancer cells that 
remain in the body after curative resection of the primary mass.  
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2.2.3 Suppression of the immune system in the perioperative 
period 
As already stated, the ultimate development of neoplastic cells that can elude 
host cellular immunity is a critical step in the formation of metastasis. Major 
surgery has been demonstrated to suppress cell-mediated immunity for 
several days after surgery (Shakhar & Ben-Eliyahu 2003). In the perioperative 
period, an increase can be observed in the release of cytokines such as IL-10 
that negatively affect cell-mediated immunity. Conversely, a reduction in the 
release of cytokines that favour cell-mediated immunity such as IL-2, IL-12 
and IFN-γ usually occurs (Snyder & Greenberg 2010). The result is a 
diminished quantity of circulating NK cells, T helper cells, dendritic cells and 
cytotoxic T-lymphocytes (Buggy & Smith 1999). A peak in immunosuppression 
is said to occur on day 3 after surgery (Coffey et al. 2003), and this may be a 
window of opportunity for the minimal residual disease to grow and spread.  
In humans, the psychological stress associated with surgery can contribute 
to perioperative immunosuppression (Andersen et al. 1998). In parallel, it has 
been shown that social conflict and aberrant fear conditioning (e.g. swim 
stress) impair the activity of NK cells in rats, augmenting lung cancer 
metastatic potential (Stefanski & Ben-Eliyahu 1996).  
However, stress is not only psychological, but also physical. Acute pain can 
suppress NK cell activity (Shavit et al. 1987; Sacerdote et al. 1994). A rat 
model demonstrated that optimizing postoperative pain management might 
attenuate the postsurgical inhibition of the host’s anti-tumour defence 
mechanisms, including NK cells (Page et al. 2001).  
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A decrease in body temperature to 30°C in rats was shown to impair the 
activity of NK cells and to reduce metastasis resistance (Ben-Eliyahu et al. 
1999). However, hypothermia of 33 - 35°C was not demonstrated to cause 
similar consequences (Melamed et al. 2003). In humans, the 
immunosuppressive effects of abdominal surgery worsened when associated 
with mild hypothermia, most likely through the stimulation of glucocorticoid 
release and sympathetic nervous system response (Belin et al. 1998). 
Perioperative allogeneic blood transfusion is another important factor that 
might be associated with an increased risk of tumour recurrence due to the 
immunosuppressive effect of allogeneic blood (Blajchman 1999).  
 
2.2.4 Effects of drugs  
2.2.4.1 Intravenous anaesthetic agents  
The possible consequences of the use of anaesthetic drugs on the activity of 
host immune system have been evaluated using in vitro and animal models in 
addition to human studies (Snyder & Greenberg 2010).  
In a rat model, thiopental and ketamine were shown to augment the quantity 
of viable lung cancer cells, while propofol and diazepam did not show a similar 
effect (Melamed et al. 2003). In the same study, the activity of NK cells was 
significantly reduced by thiopental and ketamine, but, again, not by propofol. 
Nevertheless, all three anaesthetic agents induced a substantial reduction in 
the quantity of NK cells compared with controls.  
There are studies, which advocate propofol as an inhibitor of neoplastic cell 
proliferation, supporting the theory that propofol may decrease the incidence 
of cancer recurrence and prolong survival time of human patients with cancer 
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(Deegan et al. 2009; Ye et al. 2014). Indeed, propofol and propofol conjugates 
inhibited cells growth in vitro when applied to breast cancer cell cultures at 
clinically relevant concentrations (Siddiqui et al. 2005; Ecimovic et al. 2014). 
However, findings regarding the effects of propofol on tumour cell progression 
are controversial. For instance, propofol was able to induce proliferation in 
gallbladder cancer cells (Zhang et al. 2012) and neuroblastoma cells (Wu et 
al. 2011) in vitro. The effects of propofol on breast cancer cells have been 
extensively studied (Siddiqui et al. 2005; Ecimovic et al. 2014; Lim et al. 2018). 
To the authors’ knowledge, the effects of propofol on canine mammary tumour 
cells have never been investigated. Currently, the lack of such a study does 
not allow comparisons between species on this topic. More evidence 
regarding the effects of propofol on canine mammary cancer cells would 
improve the understanding of the possible role of canine patients as a natural 
model for the study of human breast cancer. Nevertheless, the evaluation of 
propofol effects on canine mammary tumour cell proliferation, could give an 
initial indication for its advantageous clinical use in canine patients affected 
with cancer. Following these considerations, the authors decided to 
investigate with the present study the effects of propofol on canine mammary 
tumour cells proliferation and NET1 gene expression in vitro.  
 
2.2.4.2 Inhalant anaesthetic agents 
Multiple in vitro studies utilizing inhalant anaesthetic agents have shown 
effects that may have some relevance to cancer patients (Brand et al. 1997; 
Schlagenhauff et al. 2000; Benzonana et al. 2013; Zhang & Shao 2016; Lim 
et al. 2018). For instance, halothane and isoflurane impaired the stimulation 
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of NK cell cytotoxicity by IFN-γ in mice (Markovic et al. 1993). Along the same 
line, the exposure to nitrous oxide was linked with hastening of lung and liver 
metastasis growth, in a mouse cancer model (Shapiro et al. 1981). Finally, 
sevoflurane was shown to increase proliferation, migration and invasion of 
human breast cancer cells (Ecimovic et al. 2013). However, a more recent in 
vitro analysis documented the effects of blood sampled from human patients 
undergoing sevoflurane- or propofol-based anaesthesia on breast cancer cells 
apoptosis, NK cell activity and cytotoxic T-lymphocyte function. No differences 
were observed between treatments (Lim et al. 2018).  
Data from clinical trials often appear more difficult to interpret due to the 
presence of confounding variables. For instance, during surgical interventions 
patients are usually exposed to several different medications such as 
sedatives, anaesthetics, analgesics and antibiotics among others 
(Exadaktylos et al. 2006; Wigmore et al. 2016).  
Recently, sevoflurane has been utilized as a representative of the inhalant 
anaesthetic category in studies evaluating the effects of these drugs on cancer 
recurrence (Ecimovic et al. 2013; Wigmore et al. 2016; Lim et al. 2018; Hong 
et al. 2019). For this reason and to facilitate comparisons between studies, 
sevoflurane was chosen to represent inhalant anaesthetics in the present 
study. 
 
2.2.4.3 Local anaesthetic drugs and locoregional anaesthesia 
Lidocaine administered at clinical doses was shown to inhibit proliferation and 
invasive ability of human cancer cells in vitro (Mammoto et al. 2002; Sakaguchi 
et al. 2006). Ropivacaine suppressed, in vitro, the growth of cancer cells 
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derived from human patients affected with proliferative colon adenocarcinoma 
in a dose-dependent manner (Martinsson 1999). The concentrations applied 
were within the range of the therapeutic concentrations obtained inside the 
colon of patients treated rectally with ropivacaine. Conversely, in the same 
study, lidocaine, hydrocortisone and 5-aminosalicylic acid were found to be 
less potent than ropivacaine in inhibiting proliferation of human colon 
adenocarcinoma cells (Martinsson 1999). 
In a retrospective study, patients undergoing open prostatectomy and 
receiving a local anaesthetic epidurally combined with general anaesthesia 
had a 57% lower risk of cancer recurrence than patients receiving general 
anaesthesia plus opioids (Biki et al. 2008). Another retrospective study, which 
included 129 patients undergoing mastectomy and axillary clearance, showed 
a substantial reduction in tumour recurrence and metastasis when breast 
cancer surgery was performed with paravertebral anaesthesia and analgesia 
compared with general anaesthesia and morphine analgesia (Exadaktylos et 
al. 2006).  
Some multicentre randomized controlled trials have been initiated in human 
medicine. However, there is still a lack of published prospective studies 
explicitly intended to look at the effect of regional anaesthesia on the outcome 
of human or veterinary cancer patients. The presumptive ability of regional 
anaesthesia to improve long-term outcomes following cancer surgery is 
commonly linked to three diverse mechanisms (Sessler 2008). First, the 
immunosuppressive effect of surgery could be attenuated by regional 
anaesthesia (O’Riain et al. 2005). In fact, in humans undergoing breast 
surgery, paravertebral nerve blocks performed with bupivacaine 0.25% were 
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shown to prevent neuroendocrine stress response (O’Riain et al. 2005). 
Second, patients who receive regional analgesia should have lower opioid 
requirements, minimizing the negative impact of opioids on the immune 
system in terms of inhibition of cell-mediated immunity and host anti-tumour 
defences (Moller et al. 2007). Third, regional anaesthesia should reduce the 
amount of both inhalant and injectable general anaesthetics required during 
surgery itself (Snyder & Greenberg 2010). 
 
2.2.4.4 Opioids  
Perioperative and chronic administration of opioids has been proven to 
suppress humoral and cell-mediated immunity in in vitro and in human clinical 
studies (Sacerdote 2008; Sessler 2008; Liang et al. 2016; Zajączkowska et al. 
2018).  
Morphine suppresses rat and human NK cell cytotoxicity in a dose-
dependent manner (Beilin et al. 1989; Saurer et al. 2006; Boland & Pockley 
2017) and increases angiogenesis, promoting breast tumour growth in mice 
(Gupta et al. 2002). Comparably, fentanyl suppresses postoperative NK cell 
cytotoxicity in humans (Beilin et al. 1996; Boland & Pockley 2017), and 
patients receiving higher doses showed longer suppression times. In a study 
from Yeager and colleagues (1995), 23 healthy volunteers underwent 
continuous exposure to morphine for 36 hours, including an intravenous 
infusion of morphine of 0.05 mg kg-1 loading dose followed by a constant rate 
infusion of 0.03 mg kg-1 h-1 for 24 hours. Before conclusion of the morphine 
infusion, 5 participants were withdrawn from the study due to morphine-related 
side effects, such as anorexia, nausea, vomiting and pruritus. Peripheral blood 
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was sampled from the rest of the participants at five measurement times 
before, during and after morphine exposure. The results showed a significant 
suppression of NK cell cytotoxicity, persisting for 24 hours after termination of 
morphine infusion (Yeager et al. 1995). 
In contrast, a beneficial effect has been demonstrated when morphine was 
administered preoperatively in rats undergoing laparotomy (Page et al. 1998), 
suggesting a possible role for preoperative morphine administration in 
reducing surgery-induced stress and metastatic potential.  
Interestingly, tramadol, which in addition to its action at opioid receptors has 
noradrenergic and serotonergic effects, stimulates NK cells activity, in both 
rodents and humans (Gaspani et al. 2002). 
 
2.2.4.5 Non-steroidal anti-inflammatory drugs  
Neoplastic cells release prostaglandins and thereby evade host cell-mediated 
immunity (Wojtowicz-Praga 2003; Allaj et al. 2013). Non-steroidal anti-
inflammatory drugs inhibit prostaglandin synthesis via inhibition of the COX 
enzymes, demonstrating some degree of anti-tumorigenic properties (Leahy 
2002; Menter & DuBois 2012). In women with breast cancer, an 
overexpression of COX-2 enzymes has been shown (Arun & Goss 2004; Lucci 
et al. 2005). Furthermore, women taking COX-2 inhibitors for a long time 
experienced a decreased incidence of breast cancer and improved metastatic 
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2.3 In vitro cancer research 
“In vitro” comes from the Latin term "in glass". The term refers to studies of 
biological properties that are done in a test tube (i.e. in a glass vessel) rather 
than in a human being or in an animal (Ramesh et al. 2016). In vitro studies 
allow scientists to isolate specific cells, bacteria and viruses and evaluate them 
in isolation from the whole organism. Unfortunately, this means that 
sometimes results obtained during in vitro studies do not translate to in vivo 
scenarios (Mak et al. 2014).  
Relative to in vivo studies, in vitro studies are substantially faster, less 
expensive and provide fewer ethical concerns (Polli 2008). In vitro research is 
essential for making medical advances since it allows a substance to be 
studied without exposing human beings or animals to the possible side effects 
of a new drug (Gentile et al. 2017). Importantly, in vitro studies enable more 
rapid development of new treatments. Many drugs can be investigated 
simultaneously in a large number of sampled cells and only those that appear 
to be efficacious go on to in vivo studies (Hulkower & Herber 2011; Stoddart 
et al. 2011). 
 
2.3.1 Canine mammary tumour cell culture 
Cancer research has benefited immensely from the use of cancer cell lines 
(Präbst et al. 2017), which simultaneously provide a uniform sample and a 
large number of single units to analyse (Ramesh et al. 2016). Furthermore, 
cancer cell lines are suitable for study in a variety of ways and for a variety of 
applications (Stoddart et al. 2011).  
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Canine mammary tumour cell lines can be established from canine primary 
or metastatic cancer tissues, the samples of which can be obtained after 
surgical removal or euthanasia of canine patients clinically and 
histopathologically diagnosed with mammary cancer (Holliday & Speirs 2011; 
Yamauchi et al. 2012). After sampling, tumour tissue is processed for 
histopathological confirmation of the previous diagnosis. Tumour tissue is 
usually fragmented, washed and disaggregated. Thereafter, the 
disaggregated tissue suspension is centrifuged and the pelleted cells are re-
suspended in a suitable cell culture medium and maintained in a standard 
condition (i.e. 37°C in a humidified atmosphere with 5% carbon dioxide; from 
Uyama et al. 2006; Caceres et al. 2015; Osaki et al. 2016; Gentile et al. 2017). 
Accurate identification of cell lines is crucial during cell line development to 
avoid the risks of using misidentified cells (Cheung et al. 2014). 
Nowadays, the canine mammary tumour cell lines used for culture in in vitro 
studies are numerous and readily available (Norval et al. 1984; Osaki et al. 
2016; Gentile et al. 2017).  
In the present study, we utilized two cell lines of canine mammary tubular 
adenocarcinoma established by Uyama and colleagues (2006). We choose 
this pair of cell lines because deriving from the same individual, but presenting 
different evolutionary states. In fact, one cell line originated from the primary 
mass, while the other was obtained from a metastatic regional lymph node 
(Uyama et al. 2006). The aim was to verify whether the same cells in different 
evolutionary states would respond in dissimilar ways when exposed to the 
same drugs. 
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2.3.2 Tests for cancer research 
Cancer cell lines provide a convenient representation of cancers and can 
undergo several assays to investigate different aspects of cancer biology 
(Ramesh et al. 2016). Cells are routinely cultured in 6-, 12-, 24- and 96-well 
plates. Agents can be studied in several concentrations and in duplicate, 
triplicate or larger multiples to obtain meaningful and reliable results (Van 
Meerloo et al. 2013).  
Assays in general are performed for two main reasons: to ascertain the 
effects of a physical or chemical agent on the cells or to understand the 
behaviour of cells under different conditions (Ramesh et al. 2016). Available 
approaches to individuate the effects of a physical or chemical agent include 
testing cells for cytotoxicity, genotoxicity, proliferation, migration, invasion and 
changes in signalling pathways that can affect cancer cells when exposed to 
a specific agent (Korch et al. 2012; Yang et al. 2014). The assays can be 
performed on cancer cells with the aim of studying individual cells or to analyse 
the entire cell population to shed light on the physiology or behaviour of cells 
under different conditions (Borowicz et al. 2014).  
 
2.3.2.1 Proliferation 
Some in vitro assays are performed to quantify proliferation, which reflects 
cellular responses to various stimuli. These techniques help in monitoring cell 
division, the number of cells generated over time, the proliferative ability of 
cells and DNA synthesis (Präbst et al. 2017). Traditionally, proliferative assays 
are performed in drug testing to assess the effects of drugs on cell 
proliferation. Conventionally, cell proliferation has been assessed by its DNA-
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synthesizing capacity. With this technique, cell lines are incubated for a few 
hours with 3H-thymidine (a radioactive label). Proliferating cells integrate the 
radioactive label during the process of DNA synthesis, which can be visualized 
and quantified using a scintillation counter (Adan et al. 2016).  
The MTT or 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide 
cell proliferation assay is widely used for measuring cell proliferation with 
respect to cellular metabolism (Präbst et al. 2017). In fact, the MTT assay 
specifically evaluates cellular mitochondrial activity as an indicator of cellular 
viability. This technique involves a reduction of tetrazolium salts by 
mitochondrial dehydrogenase enzymes, generating reduced nicotinamide 
adenine dinucleotide and nicotinamide adenine dinucleotide phosphate. The 
resulting metabolite formazan (purple colour) can be quantified by 
spectrophotometry, measuring the absorbance at circa 570 nm. This chemical 
reaction yielding a purple product is displayed only in metabolically active 
cells, thereby eliminating non-proliferating cells (Tada et al. 1986; Weichert et 
al. 1991; Präbst et al. 2017). The MTT colorimetric assay does not involve the 
use of radioactive markers and for this reason is easy to perform (Van Meerloo 
et al. 2011).  
Moreover, cell proliferation can be achieved by measuring the amount of 
adenosine triphosphate (ATP) generated in the cells (Adan et al. 2016). This 
technique is based on the concept that dead and non-proliferating cells 
generate a negligible amount of ATP. The luciferase enzyme generates light 
in the presence of ATP, which can be efficiently detected by a luminometer. 
This assay is proficiently used to screen a large number of samples. 
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Finally, cellular proliferation can be analysed with the use of a chemical 
reaction involving the conversion of the non-fluorescent dye resazurin (blue) 
to the fluorescent dye resorufin (pink) in a reducing growth medium. The 
fluorescent signal is then measured at selected wavelengths (570 and 600 
nm).  
The rationale for selecting a method of analysis depends on several factors 
such as the experimental setting, the type of drugs used and the biological 
effects that the scientists wish to investigate. The MTT proliferation assay is 
the most commonly performed test for studying proliferation of cells exposed 
to drugs due to its simplicity of use (Rai et al. 2018). For this reason, the MTT 
method was chosen to investigate the effect of propofol and sevoflurane on 
canine mammary tumour cells proliferation in the present study. This choice 
allowed the authors to compare their data with previous studies on the topic 
of cancer cell proliferation in response to drug exposure. 
 
2.3.2.2 Migration 
For the in vitro analysis of cell migration, commonly used assays include the 
Boyden chamber assay, the scratch wound-healing assay and more recently 
the microfluidic assay (Chen & Nalbantoglu 2014).  
The Boyden chamber assay (trans-well migration assay, filter membrane 
migration assay or chemotaxis assay) can be performed quickly and employs 
chemoattractants (e.g. serum). A microporous membrane is utilized, which 
divides the culture well into two parts. In one part, usually the uppermost, the 
cells are cultured, while the lower compartment contains chemotactic agents 
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(Chen 2005). The migratory cells can be quantified using a plate reader or by 
staining of the membrane.  
In the wound-healing assay, cells are maintained as monolayer cultures. At 
80% confluence, cells are exposed to an inhibitor of cell division. After an 
adequate incubation time, a scratch (wound) is made using a sterile 
micropipette tip. The wound is observed under phase contrast inverted 
microscopy at various time intervals and its width is measured. To visualize 
the migration of cancer cells, fluorescent microscopic techniques can be used, 
and documentation of the scratch can be made using time-lapse imaging. The 
major drawback of the scratch assay is the time taken to perform the assay 
(Cory 2011).  
The microfluidic assay has the potential to be physiologically relevant for 
testing the migratory capabilities of cells when exposed to a drug. The device 
offers dual ports, where one port is used to introduce cells and the other port 
is used to deliver the drugs. The cells once introduced into the device attach 
at the port bottom, and the drug delivered through the port at the other end of 
the chamber sets up a gradient. The cells are imaged to visualize migration 
(Hulkower & Herber 2011).  
 
2.3.2.3 Invasion 
One extremely important property of malignant cells is their invasive growth 
pattern. This ability allows cancer cells to leave the compartment to which they 
are normally restricted, to gain access to connective tissues and vessels and 
to complete the initial phase of the process of metastasis (de Both et al. 1999; 
Hall & Brooks 2014). Invasive properties are in part reflected by cell shape. In 
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fact, epithelioid cells appear less invasive than spindle-shaped ones 
(Sommers et al. 1992; Boyer et al. 1996). 
To test the invasive capacity of cancer cells, numerous assay systems have 
been developed. They include the matrigel assay, the invasion in layers of 
confluent cultured fibroblasts technique and the chicken heart tissue invasion 
assay (Hall & Brooks 2014). 
The matrigel assay uses the confrontation of cancer cells with porous 
membranes coated with components of the basement membrane to assess 
their ability to penetrate the coated filter in a specific time frame (Albini et al. 
1987). 
The invasion in layers of confluent fibroblasts technique is performed using 
a co-culture of tumour cells with a confluent layer of fibroblasts to monitor the 
invasion of tumour cells into the layer (Fabra et al. 1992). Non-invasive cells 
remain on the surface of the confluent fibroblast layer, whereas invasive cells 
invade, pushing away and replacing the layer of fibroblasts. 
To perform the chicken heart assay, chicken hearts are co-cultured with 
cancer cells for some days in a suspension culture. The invading cancer cells 
can be subsequently detected in histological heart sections stained with 
haematoxylin and eosin (Mareel et al. 1979).  
 
2.3.2.4 Changes in gene expression  
Gene expression studies on cell lines provide genetic information associated 
with cellular functions such as proliferation, apoptosis, cell division, adhesion 
and intercellular communication (Ramesh et al. 2016; Caracausi et al. 2017). 
Rather than DNA, messenger ribonucleic acid (mRNA) is widely used as the 
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study material to understand the alterations in gene expression. This is due to 
the possibility of post-transcriptional changes in the sequence of DNA, which 
will be predominantly reflected in the mRNA.  
Protein estimation and detection can also predict gene expression changes 
at translational levels, and the Western blot is a common technique used for 
detection of proteins directly associated with genetic alterations (Harris 2015; 
Ramesh et al. 2016).    
 
2.3.2.4.1 Real-time polymerase chain reaction  
Real-time polymerase chain reaction (PCR) was developed in the 1990s as a 
modified version of the PCR method introduced by Kary Mullis and colleagues 
in 1986 (Mullis et al. 1986; Higuchi et al. 1992). While both methods amplify a 
specific DNA sequence more than a billion-fold, real-time PCR simultaneously 
detects the investigated DNA segment, eliminating the subsequent detection 
steps, such as agarose-gel electrophoresis, Southern blot or PCR-ELISA 
(enzyme-linked immunosorbent assay), necessary in conventional PCR. This 
makes real-time PCR less labour-intensive and less susceptible to cross-
contamination (Mackay et al. 2002; Wilhelm & Pingoud 2003; Houghton & 
Cockerill 2006).  
Before PCR was introduced, the ability to detect a specific DNA sequence 
was limited by its initial quantity in the sample investigated. Polymerase chain 
reaction eradicates this limitation by producing numerous copies of the 
targeted DNA segment using enzymes called polymerases. Polymerases are 
present in all living cells and their task is to copy, proofread and correct genetic 
material (Powledge 2004). Taq-polymerase (from Thermus aquaticus) is a 
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frequently used enzyme in PCR (Valasek & Repa 2005). Primers, two strands 
of nucleotides complementary to the sequence of nucleotides on either side 
of the sought DNA section, tell the polymerases where to begin the synthesis. 
They are individually created in the laboratory or acquired from commercial 
suppliers.  
Generally, PCR involves three steps: 1) denaturation à separating the 
double-stranded DNA (dsDNA) by heating to over 90°C, 2) annealing à 
binding of the primers and 3) DNA synthesis by polymerases (Figure 1; from 
www.thermofisher.com). In real-time PCR, the DNA segment under 
investigation, is amplified and detected at the same time by measuring 
fluorescence changes.  
There are different detection formats available, which differ in their method 
of generating a fluorescence signal proportional to the amplification products 
by using different so-called probes. The earliest and simplest way is to use 
dsDNA-specific dye (e.g. ethidium bromide, YOYO-1 and SYBR-green). In 
contrast to other detection assays, the fluorophores bind sequence-
independently to all dsDNA, making the design of a specific probe obsolete 
(Powledge 2004). 
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 Figure 1: Individual steps of PCR: 1) denaturation, 2) annealing, 3) extension 
(www.thermofisher.com). 
 
2.3.2.4.2 Quantitative assay for gene expression (quantitative PCR) 
The quantitative polymerase chain reaction (qPCR) technique has been 
incorporated into laboratory routine by various researchers working on cancer 
cell lines. This technique is able to quantify the number of copies of a target 
gene in a specific sample or cell line treated with a specific molecule. Such 
studies are also useful for analysing various metabolizing genes that indicate 
drug effects (AbuHammad & Zihlif 2013).  
The basis of this assay is a PCR performed on complementary DNA 
(cDNA), where the generated amplification curves are analysed to estimate 
the initial template amount of the specific gene (i.e. target gene). The 
amplification curve consists of three phases: 1) the initial lag phase, 2) the 
exponential phase and 3) the plateau phase (Figure 2; from Rodriguez-Lazaro 
& Hernandez 2013). In the exponential phase, the fluorescence signal 
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increase correlates directly with the product increase. The estimate of the 
initial template amount is based on the number of cycles needed for the signal 
to reach an arbitrary threshold, the so-called cycle threshold (Ct) value, shown 
as the intersection point or crossing point of the signal curve in its exponential 
phase with the threshold (Figure 2). The Ct value is indirectly proportional to 
the template amount of the target gene (Wilhelm & Pingoud 2003). 
The NET1 gene is related with tumour cell migration. The study of NET1 
gene expression through qPCR was performed in the present project to 
evaluate possible changes in cell behaviour associated to the exposure of 
canine mammary cancer cells to propofol and sevoflurane. 
 
Figure 2: Polymerase chain reaction amplification curve comprising three phases: 1) the initial 
lag phase, 2) the exponential phase and 3) the plateau phase. Ct = cycle threshold; Cp = 




 Review of the literature
   
 53 
2.4 NET1 protein  
The NET1 protein is a RhoA-specific GEF and was first identified as an 
oncogene in neuroepithelioma cells (Chan et al. 1996). The proteins encoded 
by NET1 gene primarily interact with RhoA, which is a member of the Rho 
family of small guanosine triphosphate hydrolase enzymes (GTPases; from 
Alberts et al. 1998). The Rho GTPases function as molecular switches of 
signalling cascades controlling a variety of cell functions, including actin 
cytoskeleton organization, cell polarity, cell adhesion and cell motility (Hall 
1998; Bishop & Hall 2000; Bokoch 2000; Etienne-Manneville & Hall 2002; 
Stamnes 2002; Begum et al. 2004; Jaffe & Hall 2005).  
The GTPases change between their active and inactive conformation by 
either binding guanosine triphosphate (GTP) or guanosine diphosphate 
(GDP). Several proteins regulate this fluctuation. Guanine nucleotide 
exchange factors catalyse the release of GDP and the binding of GTP, thus 
activating Rho GTPases. The GTPase-activating proteins increase the 
intrinsic GTP hydrolysis activity in order to enter the inactive state, and 
guanine nucleotide dissociation inhibitors maintain a cytosolic reserve of GDP-
bound Rho proteins ready for activation (Rossman et al. 2005; Bos et al. 
2007).  
In cancer research the NET1 protein has a fundamental role in the 
organization of actin filaments in the cytoskeleton, and its overexpression has 
been demonstrated to increase the ability of human breast adenocarcinoma 
cells to migrate and invade (Glicrease et al. 2009).  
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2.4.1 RhoA in cancer biology 
The RhoA protein family and the NET1 gene are especially noteworthy in the 
context of EMT. Figure 3 shows EMT during tumour dissemination and 
emphasizes the necessity of the reverse mechanism, the so-called 
mesenchymal-to-epithelial transition (MET), to form a metastatic lesion at a 
new site (Heerboth et al. 2015).  
As mentioned above, small RhoA GTPases regulate cellular functions such 
as cell invasion and metastasis formation. They are crucial in the amoeboid 
and mesenchymal migration (Friedl & Wolf 2003) and in the regulation of 
metalloproteinases (Lozano et al. 2003), which facilitate cell invasion by 
degrading the extracellular matrix (Stetler-Stevenson 2001). Increased RhoA 
activity has been connected to the transformation of mice embryo fibroblast 
cells (i.e. NIH 3T3) into an invasive fibroblastoid phenotype (Sander et al. 
1999). Accordingly, expression and activity of RhoA were found to be 
enhanced in several human cancers (Kamai et al. 2001; Fukui et al. 2006; 
Horiuchi et al. 2008; Gilkes et al. 2014) and have been linked to multiple steps 
in tumour progression (Vega & Ridley 2008). Increased expression of RhoA 
was strongly related to poor prognosis in human hepatocellular carcinoma 
(Fukui et al. 2006; Hu et al. 2013) as well as in oesophageal squamous cell 
carcinoma, ovarian carcinoma and testicular germ cell tumour (Kamai et al. 
2001; Faried et al. 2005; Horiuchi et al. 2008), while the suppression of RhoA 
signalling stimulated apoptosis of gastric cancer cells (Xu et al. 2012). 
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Figure 3: Type 3 epithelial-to-mesenchymal transition (EMT) during tumour dissemination. 
Blue = primary epithelial tumour cells; green = stromal cells; purple = cell-to-cell receptors and 
integrins; red/blue = cells undergoing EMT; red = invasive mesenchymal cells. ECM = extra 
cellular matrix; MET = mesenchymal-to-epithelial transition (Heerboth et al. 2015). 
 
2.4.2 Regulation of NET1 
There are numerous ways in which NET1 can be regulated on a transcriptional 
level. Dutertre and colleagues (2010) reported that oestrogens and 
progesterone were able to increase NET1 transcription in breast cancer cells. 
In pigmented epithelial cells and human keratinocytes, transforming growth 
factor beta (TGF-b) stimulates NET1 by small mother against decapentaplegic 
(Smad) 2/3 proteins and extracellular signal-regulated kinases 1/2 -dependent 
pathways, respectively (Shen et al. 2001; Lee et al. 2010; Papadimitriou et al. 
2011). Other studies have reported an increase in NET1 expression levels 
mediated by IL-2 in human lymphocytes (Mzali et al. 2005) and by tumour 
necrosis factor alpha together with lysophosphatidic acid (LPA) in gastric 
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cancer cells (Leyden et al. 2006; Murray et al. 2008). Gene expression-
regulating non-messenger single-strand RNAs or micro-RNAs (miRs) have 
been associated with NET1 regulation as well (Ambros 2004). In particular, 
miR-22 regulates NET1 expression in leukaemia cells, while miR-24 
decreases NET1 mRNA levels in human keratinocytes (Papadimitriou et al. 
2011; Ahmad et al. 2014). 
Although sub-cellular localization, post-translational modification and 
degradation are considered the main regulators of proteins encoded by NET1, 
many specific stimuli and molecular mechanisms are still unknown. Another 
possible means of regulation is so-called nuclear sequestration. The NET1 
protein is activated when it is relocated from the nucleus to the cytoplasm 
(Schmidt & Hall 2002). More recent studies have found that this relocation can 
be stimulated by epidermal growth factor and Ras-related C3 botulinum toxin 
substrate 1 (Rac1) proteins (Carr et al. 2013a; Song et al. 2015; Ulu & Frost 
2016), while LPA leads to cytoplasmic accumulation (Song et al. 2015).  
 
2.4.3 NET1, EMT and cancer progression  
There are numerous studies investigating the role of NET1 in cancer 
progression. The NET1 protein promotes EMT through various mechanisms, 
e.g. it is critical for TGF-b1-induced cytoskeletal reorganization and N-
cadherin expression (Figure 4; from Lee et al. 2010) and is involved in the 
regulation of cell-to-cell contacts (Carr et al. 2009). The NET1 protein was 
found to be overexpressed in human gastric adenocarcinoma, hepatocellular 
carcinoma and breast adenocarcinoma, and its knockdown decreased cell 
invasion and migration (Leyden et al. 2006; Murray et al. 2008; Shen et al. 
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2008; Carr et al. 2013b). An increased NET1 expression was noted in 
oesophageal cancer, and its high expression was an independent prognostic 
factor for lymph node metastasis (Lahiff et al. 2013). Similarly, NET1 has been 
proposed as a prognostic marker and a potential therapeutic target for non-
small cell lung cancer due to its strong association with lymph node 
metastasis, distant metastasis and differentiation degrees (Fang et al. 2015). 
In patients with gliomas, a higher NET1 protein level correlated with higher 
tumour grades and lower median survival (Tu et al. 2010). Finally, dual 
silencing of NET1 and survivin effectively inhibited proliferation in skin 
squamous cell carcinoma (Ji et al. 2015). 
In vitro studies have shown that expression of NET1 in human tumour cells 
can be influenced by drugs used in the perioperative period. In particular, 
Ecimovic and co-workers (2014) showed that human breast cancer cells 
cultured under propofol exposure significantly decreased NET1 expression, 
reducing cell migration, a phenomenon that was reversed after NET1 
silencing.  
Human breast cancers and canine mammary tumours have several 
common characteristics (Yamagami et al. 1996; Chia et al. 2005; Morris et al. 
2009; Queiroga et al. 2011; Ranieri et al. 2013; Alvarez 2014; Liu et al. 2014; 
Telli & Sledge 2015), which recently brought to the recognition of canine 
mammary tumours as a translational model of naturally occurring breast 
cancer in people (Alvarez 2014). However, there is a lack of studies 
investigating the expression of the NET1 gene in canine mammary tumour 
cells. Based on these considerations, the authors considered relevant to 
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explore the expression of NET1 gene in canine mammary tumour cells 











Figure 4: Mechanism of neuroepithelial transforming 1 (NET1) gene-dependent transforming 
growth factor (TGF)-b-induced epithelial-to-mesenchymal transition in retinal pigment 
epithelia cells. Stimulation of TGF-b leads to cytoskeleton reorganization via NET1-induced 
Ras homologue gene family, member A (RhoA)  activation. GTP = guanosine triphosphate; 
LIMK-P = LIM protein kinase phosphorylated; ROCK = Rho-associated protein kinase; Smad 
= small mother against decapentaplegic protein; TF = transcription factor (Lee et al. 2010).  
  
2.5 Rationale 
Regardless of the introduction of new adjuvant therapies, surgical removal of 
primary lesions remains the treatment of choice for human breast cancer and 
canine mammary tumours (Singletary et al. 2003; Sorenmo 2003; Chia et al. 
2005; Karayannopoulou & Lafioniatis 2016). This exposes human and canine 
patients affected with cancer to repeated anaesthetic events. In recent years, 
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it became strong the evidence that some anaesthetics are able to influence 
cancer and metastasis free time (Heaney and Buggy 2012, Bajwa et al. 2015, 
Byrne et al. 2016, Laudanski et al. 2016, Sekandarzad et al. 2017). Propofol 
and sevoflurane represent the most commonly used drugs in studies 
evaluating the effects of general anaesthetics on cancer progression in 
humans (Siddiqui et al. 2005; Wada et al. 2007; Deegan et al. 2009; Ecimovic 
et al. 2013; Song et al. 2014; Ye et al. 2014; Wigmore et al. 2016). However, 
studies evaluating the effects of these anaesthetics on cancer progression in 
veterinary patients are lacking. Following these considerations, the authors 
decided to investigate the effects of propofol and sevoflurane on canine 
mammary cancer cells. 
Several techniques are described to asses metastatic potential of cancer 
cells in vitro (Korch et al. 2012; Borowicz et al. 2014; Yang et al. 2014). 
Nevertheless, the study of tumour cell proliferation has been advocated as a 
central element for the judgment of cancer malignant behaviour (Cooper 2000; 
Adan et al. 2016; Präbst et al. 2017). Being, in veterinary medicine, the study 
of the effects of anaesthetics on cancer recurrence at its arbour, the authors 
choose the MTT proliferation test as a preliminary assay for the investigation 
of cancer cell behaviour. 
The NET1 gene has been associated with increased invasion and migration 
of tumour cells in human medicine (Kamai et al. 2001; Fukui et al. 2006; 
Horiuchi et al. 2008; Glicrease et al. 2009; Gilkes et al. 2014). Particularly, its 
expression has been studied in human breast cancer cells where the exposure 
to propofol decreased NET1 expression significantly (Ecimovic et al. 2014). 
To the author’s knowledge, the expression of NET1 gene in canine mammary 
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cell lines have not been previously investigated. Considering the growing 
interest in human medicine for the study of genes associate with cancer 
development, we decided to investigate the expression of NET1 gene in 
canine mammary tumour cells. 
Several similarities between canine and human mammary cancers brought 
to the recognition of canine patients as potentially suitable natural models for 
translational medicine (Queiroga et al. 2011, Alvarez 2014). Therefore, new 
findings in this research field could help optimize perioperative planning for 
oncologic surgery in both veterinary and human patients. Moreover, new 
insights could encourage investigations into propofol potential as an anti-
cancer therapeutic agent. 
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3. AIMS OF THE STUDY 
 
This project was designed to evaluate in vitro the effects of clinically available 
formulations of propofol and sevoflurane on cell proliferation and expression 
of the NET1 gene in two different canine mammary tumour cell lines.  
 
Detailed aims were as follows: 
1. To investigate the effects of propofol exposure on canine mammary 
tumour cell proliferation rate (Study I). 
2. To investigate the effects of propofol exposure on canine mammary 
tumour cell NET1 expression (Study II). 
3. To investigate the effects of sevoflurane exposure on canine mammary 
tumour cell proliferation rate (Study III). 
4. To investigate the effects of sevoflurane exposure on canine mammary 
tumour cell NET1 expression (Study III). 
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4. MATERIALS AND METHODS 
 
4.1 Cell culture  
All three studies presented here were performed at the Laboratory of 
Pathology of the Department of Veterinary Sciences - Surgery Unit, at the 
Veterinary Faculty of the University of Turin (Italy). We utilized two cell lines 
established by Uyama and colleagues in Japan (2006). This pair of canine 
mammary tubular adenocarcinoma cell lines derives from a 10-year-old intact 
female Shih Tzu dog and was established from tissues obtained after surgical 
intervention. The primary cell line (CIPp) originated from the primary mass of 
a tubular adenocarcinoma, and the metastatic cell line (CIPm) originated from 
tubular and solid material from a metastatic regional lymph node (Uyama et 
al. 2006). Cells were first grown in Roswell Park Memorial Institute medium 
supplemented with 10% foetal bovine serum (Sigma-Aldrich, St. Louis, MO, 
USA), 100 μg mL-1 penicillin (Sigma-Aldrich, St. Louis, MO, USA), 100 μg mL-
1 streptomycin (Sigma-Aldrich, St. Louis, MO, USA), 1.5 mg mL-1 amphotericin 
B (Sigma-Aldrich, St. Louis, MO, USA) and incubated for 24 hours at 37°C in 
a humidified atmosphere with 5% carbon dioxide.  
 
4.2 Drug exposure  
Drug exposure, in terms of concentrations and times during each study, is 
summarized in Figure 5. 
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4.2.1 Propofol 
In Studies I and II, cells were exposed to different concentrations of a clinically 
accessible propofol preparation including a lipid-based emulsion (soybean oil, 
100 mg mL-1; glycerol, 22.5 mg mL-1; egg lecithin, 12 mg mL-1) and sodium 
hydroxide adjuvant to regulate the pH (LE propofol; 10 mg mL-1; Vetofol, 
Esteve SpA, Milan, Italy).  
In Study I, LE propofol was diluted with cell medium to 1, 5 or 10 μg mL-1 
(P1, P5 and P10 treatments, respectively) prior to incubating the cells. Medium 
containing LE propofol was subsequently added to the cell cultures for 6 and 
12 hours. The experiment was performed six times for each condition, and 
cells grown in culture medium alone were used as a control (C). 
In Study II, cells were treated with LE propofol diluted with cell medium to 1 
and 10 μg mL-1 (P1 and P10 treatments, respectively) for 6, 12, 24 and 48 
hours. The experiment was performed in triplicate, and cells cultured without 
anaesthetics were used as a baseline condition (B).  
The chosen concentrations correlated with described blood levels of 
propofol in greyhounds (Hughes & Nolan 1999) after the provision of clinically 
applicable doses intravenously (i.e. 4 mg kg-1 followed by infusions of 0.2 - 0.4 
mg kg-1 min-1).  
 
4.2.2 Sevoflurane 
In Study III, a clinically available sevoflurane formulation (Sevorane, AbbVie 
Oy, Espoo, Finland) was utilized for the treatments at three different 
concentrations: 1, 2.5 or 4 mM (S1, S2.5 and S4 treatments, respectively). 
  Materials and methods 
   
 64 
Cells grown only in the culture medium were used as a control. Medium 
containing sevoflurane (S1, S2.5 and S4 concentrations) was added every 
hour to the cell culture to avoid decreases in drug concentration over time due 
to evaporation, as suggested by Ecimovic and colleagues (2013). The 
sevoflurane concentrations were chosen since they were previously used in a 
study in human medicine where sevoflurane was applied on breast cancer 
cells to investigate changes in cell proliferation, migration and invasion 
(Ecimovic et al. 2013).  
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Figure 5: Summary of study designs. In Study I, primary (CIPp) and metastatic (CIPm) 
canine mammary tubular adenocarcinoma cells were exposed to different concentrations of a 
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lipid-based propofol emulsion (P1: 1 μg mL-1; P5: 5 μg mL-1; P10: 10 μg mL-1) or cultured in a 
control cell culture medium (C). After 6 and 12 hours of exposure, absorbance was compared 
between treated cells and controls. In Study II, CIPp and CIPm were exposed to P1 and P10 
or cultured in a baseline cell culture medium (B). After 6, 12, 24 and 48 hours of exposure, 
cells were lysed and the concentration of neuroepithelial transforming gene 1 (NET1) was 
compared between treated cells and baseline. In Study III, CIPp and CIPm cells were exposed 
to different concentrations of a commercially available sevoflurane formulation (S1: 1 mM; 
S2.5: 2.5 mM; S4: 4 mM) or cultured in a control cell culture medium. After 6 hours of 
exposure, absorbance was compared between treated cells and controls. Subsequently, CIPp 
and CIPm cells were exposed to S1 and S4 or cultured in a baseline cell culture medium, and 
after 6 hours of exposure cells were lysed and the concentration of NET1 was compared 
between treated cells and baseline.   
 
4.3 Proliferation assay 
In Studies I and III, cell proliferation after the exposure to propofol and 
sevoflurane was evaluated in both cell lines with the use of a MTT colorimetric 
assay for cell survival and proliferation (MTT, Sigma Aldrich, St. Louis, MO, 
USA), performed according to Tada and co-authors (1986). This technique 
quantifies the conversion of MTT into purple formazan crystals, which are 
produced by redox activity of living cells. A lessening of cellular redox activity 
implies a decrease in cell viability (Van Meerloo et al. 2011). 
Previously, cells were cultured in a 75 cm2 standard tissue culture flask 
(Sarstedt Ltd., Dublin, Ireland) as monolayers. Media were changed every 3 
days. Before each experiment, cells were harvested from 70% confluent 
cultures by trypsinization and quantified with an automated cell counter 
(Automated Cell Counter TC20, Bio-Rad, Milan, Italy).  
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The time-dependent exponential cell growth curve was preliminarily 
evaluated at 4, 6 and 12 hours for each cell line to define ideal experimental 
settings. Cells were seeded into a normal cell culture medium in a range from 
1000 to 10 000 cells per well. The trial was performed in a 96-well plate in 
triplicate (Eppendorf Cell Culture Plate, Eppendorf S.r.l., Milan, Italy) and a 
proliferation index was obtained with the MTT colorimetric assay (see below). 
On the basis of the resulting time-dependent exponential cell growth curve, a 
concentration of 3000 cells per well was found to be the most appropriate to 
show time-related cell growth (e.g. no indications of cell death consequent to 
over-confluence) and was therefore selected for assessing cell proliferation 
during 6 and 12 hours of exposure to treatments. Thus, cells were seeded at 
a density of 3000 cells per well for a total of 6 experimental wells in a 96-well 
cell culture plate (Eppendorf Cell Culture Plate, Eppendorf S.r.l., Milan, Italy) 
and incubated with 100 μL of normal cell culture medium for 12 hours to allow 
homogeneous cell adhesion.  
Once the different exposure times were reached, the solutions containing 
treatments with propofol or sevoflurane were removed. Afterwards, 20 μL of 
MTT diluted in phosphate-buffered saline at a 5 mg mL-1 concentration and a 
7.5 pH was supplemented to every well and incubated for 4 hours at 37°C. 
Following the initial incubation period, 0.1 mL of 10% sodium dodecyl sulphate 
(Sigma-Aldrich, St. Louis, MO, USA) diluted in a solution of 0.01 M 
hydrochloric acid was supplemented to every well to dissolve the formazan 
crystals and incubated overnight. Subsequently, quantifications were obtained 
with a spectrophotometer (Microplate Model 680, Bio-Rad, Milan, Italy) on an 
ELISA plate reader at 590 nm. A total value of absorbance was obtained. 
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Absorbance values inferior to those of controls indicated a decrease in cell 
proliferation rate, while values higher than those of controls indicated an 
increase in cell proliferation rate (Van Meerloo et al. 2011). 
 
4.4 Quantitative PCR  
In Studies II and III, a qPCR was performed to evaluate the expression of 
NET1 after treatment exposure.  
Three hundred thousand cells were seeded in triplicate in 6-well culture 
plates (Eppendorf Cell Culture Plate, Eppendorf S.r.l., Milan, Italy). After about 
6 hours of incubation to permit cell attachment, they were exposed to the 
aforementioned concentrations of propofol and sevoflurane for 6 and 12 hours 
in the case of propofol, and for 6 hours only in the case of sevoflurane. In 
Study III, as in the protocol for the MTT assay, the same concentrations of 
sevoflurane were added to the cell cultures every hour to compensate for the 
evaporation tendency of this agent. Cells cultured without treatment were used 
as controls.  
To isolate total ribonucleic acid (RNA), culture media were removed from 
the cell cultures at the end of the treatment, and 0.5 mL of a ready-to-use 
reagent designed to isolate high-quality total RNA (TRIzol, Sigma-Aldrich, 
Dublin, Ireland) was added to each well to lyse the cells, according to the 
manufacturer’s instructions. Once a microscopic examination revealed cells to 
be lysed, the cell lysate was transferred to a clean 1.5 mL microfuge tube. 
Thereafter, 200 μL of chloroform was added. The mixture was gently shaken, 
left at room temperature (25°C) for 15 minutes and centrifuged at 13 000 g for 
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15 minutes at 4°C. The upper aqueous layer was transposed into another 
clean 1.5 mL tube carefully without touching the genomic and protein-
containing interphase. A total of 0.5 mL of ice-cold isopropanol was added to 
the aqueous phase, the tube was gently shaken and left to stand on ice for 10 
minutes before being centrifuged at 13 000 g for another 10 minutes at 4°C. 
The supernatant was removed and 1 mL of sterile ethanol (75%) was added 
in order to wash the pellet by gently centrifuging (7500 g for 5 minutes). After 
ethanol removal, the pellet was allowed to air dry for 5 minutes before being 
re-suspended in 50 μL of nuclease-free water by heating it at 60°C for 15 
minutes. Total RNA was quantified with an automated electrophoresis system 
(Experion Electrophoresis System, Bio-Rad, Milan, Italy), and cDNA was 
synthesized from 1 µg of total RNA using a reverse transcription kit 
(QuantiTect Reverse Transcription kit, Qiagen, Milan, Italy). According to the 
manufacturer’s instructions, 1 µg of total RNA was incubated with 2 μL of 
deoxyribonuclease buffer (gDNA Wipeout Buffer, Qiagen, Milan, Italy) and 
ribonuclease-free water to reach a total volume of 14 μL for 2 minutes at 42°C 
and then left for 10 minutes on ice. Thereafter, 1 μL of reverse transcriptase 
(Quantiscript Reverse Transcriptase, Qiagen, Milan, Italy), 4 μL of a dedicated 
buffer (Quantiscript RT Buffer 5X, Qiagen, Milan, Italy) and 1 μL of a dedicated 
primer mix (RT Primer mix, Qiagen, Milan, Italy) were added and incubated 
for 15 minutes at 42°C, followed by 3 minutes at 95°C to inactivate the reverse 
transcriptase. To evaluate the relative amount of specific NET1 transcript, 1 
μL of cDNA obtained as previously described was used for qPCR. Briefly, 1 
μL of cDNA was subjected to qPCR with a dedicated detection chemistry 
system (IQ SYBR Green Supermix, Bio-Rad, Milan, Italy) and an optical 
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software system (IQ5 Optical System Software, Bio-Rad, Milan, Italy). Primer 
sequences are listed in Table 5 (Argano et al. 2017). 
The reaction conditions were reverse transcription for 3 minutes at 95°C (1 
cycle), followed by denaturation for 30 seconds at 95°C, and annealing for 30 
seconds at 60°C (35 cycles). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression levels were used to normalize NET1 expression.  
Values for delta cycle threshold (ΔCt) were obtained in triplicate for each 
sample. Gene expression was calculated using a relative quantification assay 
corresponding to the comparative Ct method: the amount of target gene, 
identified through its cycle threshold, was normalized by subtracting the cycle 
threshold of the endogenous housekeeping gene (GAPDH). These sample 
ΔCt values were related to the appropriate controls with linear models (see 
below).  
 
Table 5: Primer sequences used in quantitative PCR (Argano et al. 2017). 
Primer Gene Sequence 
Forward NET1 5’-CATCAAGAGGACGATCCGGG-3’ 
Reverse NET1 5’-ATTGCTTGGCTCCTCTTGCT-3’ 
Forward GAPDH 5'-GGCACAGTCAAGGCTGAGAAC-3' 
Reverse GAPDH 5'-CCAGCATCACCCCATTTGAT-3' 
 
4.5 Statistical analysis  
In Study I, the mean absorbance value from controls was compared with mean 
absorbance values from treatments using a 3-way ANalysis Of VAriance 
  Materials and methods 
   
 71 
(ANOVA) with time, cell line and concentration of LE propofol as factors. 
Normality of residuals, which is an assumption of linear models, was tested 
with a Shapiro-Wilks test of normality of residuals. Approximate equality of 
variances within groups was checked by visual inspection. Data obtained with 
the MTT assays are presented as mean ± standard error and ranges for the 
percentage increases or decreases of cell proliferation rates.  
In Studies II and III, one overall mean value of ΔCt was used for statistical 
analysis per biological sample (i.e. mean values of the technical triplicates). 
Amplification with qPCR is inherently an exponential process, such that the 
error structure is approximately linear in  Ct values (and linear in the log of the 
inferred number of molecules). Hence, an analysis with linear models is 
indicated (Pfaffl 2001). 
In Study II, ΔCts were compared using a 3-way ANOVA test (time, cell line, 
concentration of LE propofol as factors) or a Student T-test as relevant. Data 
are presented as mean ΔCt values over time for both cell lines.  
In Study III, a 2-way ANOVA test was performed for the evaluation of cell 
proliferation using as target variables the mean values of absorbance at 6 
hours of treatment, while treatments (the three sevoflurane concentrations and 
the control) and cell types (primary and metastatic cells) were used as 
explanatory variables. Similarly to Study I, data obtained with the MTT assays 
are presented as mean ± standard error and ranges for the percentage 
increases or decreases of cell proliferation rates.  
One-way ANOVA tests were used in Study III to analyse the expression of 
NET1; the target variables were mRNA expressions of NET1 and the 
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treatments (two sevoflurane concentrations, S1 and S4, and the control) were 
the explanatory variables.  
In all sets of ANOVA tests, pairwise differences between treatments and 
controls were tested for significance. A value of p < α = 0.05 was considered 
statistically significant. Tests for the correction for multiple comparisons were 
not performed.  
All statistical analyses were performed with an open-source statistical 
software package (R-studio, version 3.2.0, Boston, MA, USA; www.r-
project.org).
  Results 




5.1 Cell proliferation under propofol treatments (I) 
A Shapiro-Wilks test of the residuals indicated no deviation from normality.  
After 6 hours of exposure, no significant differences were found in CIPp 
between the mean absorbance value of the P1 treatment group and that of 
control cells. Treatments P5 and P10 showed a significant increase (p = 
0.0137 and p = 0.0005) in cell proliferation rate of 18% and 27%, respectively 
(Figure 6 A; from Argano et al. 2019a). In CIPm cells at the same incubation 
time, no significant changes were noticed in cell proliferation between control 
and any LE propofol-treated cell (Figure 6 B; from Argano et al. 2019a).  
After 12 hours of exposure, all LE propofol concentrations produced a 
significant increase in cell proliferation in CIPp cells (Figure 7 A; P1 = 105% p 
= 7.48e-07;  P5 = 114% p = 2.32e-07; P10 = 123% p = 6.94e-08; from Argano 
et al. 2019a) and a significant decrease in cell proliferation in CIPm cells 
(Figure 7 B; P1 = -22% p = 0.0001; P5 = -14% p = 0.0075; P10 = -22% p = 
0.0002; from Argano et al. 2019a). 
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Figure 6: Changes in absorbance values between primary (A; CIPp) and metastatic (B; CIPm) 
canine mammary tubular adenocarcinoma cells exposed to different concentrations (P1: 1 μg 
mL-1; P5: 5 μg mL-1; P10: 10 μg mL-1) of a lipid-based propofol emulsion compared with control 
cells (C) after 6 hours of drug exposure. Significantly different comparisons are indicated by 
asterisks (**: p < 0.01; *: p < 0.05; from Argano et al. 2019a). 
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Figure 7: Changes in absorbance values between primary (A; CIPp) and metastatic (B; CIPm) 
canine mammary tubular adenocarcinoma cells exposed to different concentrations (P1: 1 μg 
mL-1; P5: 5 μg mL-1; P10: 10 μg mL-1) of a lipid-based propofol emulsion compared with control 
cells (C) after 12 hours of drug exposure. Significantly different comparisons are indicated by 
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5.2 NET1 expression under propofol treatments (II) 
Expression of NET1 gene was detected in both primary and metastatic cell 
lines cultured without propofol in the sole culture medium. A significantly 
higher NET1 expression was observed in CIPp compared to CIPm without 
drug exposure (median ΔCt 5.82 and 6.48, respectively; p = 0.0004).  
Tables 6 and 7 report the mean ΔCt values observed over time for CIPp 
and CIPm, respectively, after exposure to P1 and P10 (Argano et al. 2017).  
 
Table 6: Neuroepithelial transforming gene 1 (NET1) expression reported as mean delta cycle 
threshold (ΔCt) values in the primary canine tubular adenocarcinoma cells (CIPp) after 6, 12, 
24 and 48 hours of exposure to P1 (A; 1 µg mL-1) or P10 (B; 10 µg mL-1; from Argano et al. 
2017). 
A	 CIPp	 B	 CIPp	
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Table 7: Neuroepithelial transforming gene 1 (NET1) expression reported as mean delta cycle 
threshold (ΔCt) values in the metastatic canine tubular adenocarcinoma cells (CIPm) after 6, 
12, 24 and 48 hours of exposure to P1 (A; 1 µg mL-1) or P10 (B; 10 µg mL-1; from Argano et 
al. 2017). 
A	 CIPm	 B	 CIPm	










After 6 hours of exposure, CIPp cells treated with both concentrations of LE 
propofol showed a significantly higher (P1 p = 0.0373; P10 p = 0.0104) NET1 
expression than at baseline (Figure 8; from Argano et al. 2017). In CIPm cells, 
a significant difference (p = 0.0202) was found between baseline and the 
higher concentration of LE propofol, the latter showing lower gene expression 
(Figure 9; from Argano et al. 2017). After 12 hours of exposure, in CIPp cells 
NET1 mRNA levels were significantly decreased with both concentrations of 
LE propofol (P1 p = 0.0004; P10 p = 4.80e-06; Figure 8). In CIPm cells, NET1 
expression was significantly decreased (p = 0.0261) with the higher 
concentration of LE propofol compared with baseline (Figure 9). After 24 hours 
of exposure, in CIPp cells both concentrations of LE propofol induced a 
significant reduction (P1 p = 2.67e-05; P10 p = 0.0007) in NET1 expression 
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compared with baseline (Figure 8). No significant differences were found at 24 
hours in CIPm cells. After 48 hours of exposure, in CIPp cells the higher 
concentration of LE propofol induced a significant increase (p = 0.0361) in 
gene expression compared with baseline (Figure 8). No significant differences 
were found at 48 hours in CIPm cells. 
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Figure 8: Means and standard errors of fold changes (ΔCt) over time at 6, 12, 24 and 48 hours 
(h) of exposure in neuroepithelial transforming gene 1 (NET1) expression in primary canine 
tubular adenocarcinoma cells (CIPp) exposed to different concentrations of a lipid-based 
propofol emulsion (A; P1 = 1 µg mL-1 and B; P10 = 10 µg mL-1) versus baseline. Significantly 
different comparisons to the baseline are indicated by asterisks (* = p < 0.05, *** = p < 0.005; 
from Argano et al. 2017).  
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Figure 9:  Means and standard errors of fold (ΔCt) over time at 6, 12, 24 and 48 hours (h) of 
exposure in neuroepithelial transforming gene 1 (NET1) expression in metastatic canine 
tubular adenocarcinoma cells (CIPm) exposed to different concentrations of a lipid-based 
propofol emulsion (A; P1 = 1 µg mL-1 and B; P10 = 10 µg mL-1) versus baseline. Significantly 
different comparisons to the baseline are indicated by asterisks (* = p < 0.05; from Argano et 
al. 2017).  
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5.3 Cell proliferation under sevoflurane treatments (III)    
Normal distribution of residuals was confirmed by a Shapiro-Wilks test.  
A significant increase in cell proliferation rate relative to controls was 
observed in CIPp treated with S1 and S2.5 (Figure 10 A; 23% p = 0.0519 and 
13% p = 0.0083, respectively; from Argano et al. 2019b). Conversely, a 
significant decrease in cell proliferation rate was found in CIPm treated with 
all of the tested concentrations of sevoflurane (Figure 10 B; S1 = -33% p = 
4.38e-06; S2.5 = -41% p = 2.36e-07; S4 = -62% p = 2.59e-10; from Argano et 
al. 2019b).  
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Figure 10: Means and standard errors of absorbance values between primary (A; CIPp) and 
metastatic (B; CIPm) canine mammary tubular adenocarcinoma cells exposed to different 
concentrations (S1: 1 mM; S2.5: 2.5 mM; S4: 4 mM) of a commercially available sevoflurane 
formulation compared with control cells (C). Significantly different comparisons are indicated 
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5.4 NET1 expression under sevoflurane treatments (III) 
Neither sevoflurane concentration (S1 or S4) induced a significant change in 
NET1 expression in CIPp cells compared with baseline (Figure 11 A; from 
Argano et al. 2019b). A significant increase (p = 0.0468) in gene expression 
was observed only in CIPm between cells treated with S4 and baseline (Figure 
11 B; from Argano et al. 2019b). 
Figure 11: Means and standard errors of fold changes (ΔCt) in neuroepithelial transforming 
gene 1 (NET1) expression in primary (A; CIPp) and metastatic (B; CIPm) canine mammary 
tubular adenocarcinoma cells exposed to different concentrations (S1: 1 mM; S4: 4 mM) of a 
commercially available sevoflurane formulation. Significantly different comparisons are 
indicated by asterisks (*: p < 0.05; from Argano et al. 2019b).
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In the present study we demonstrated that the highest, but still clinically 
applicable,  concentrations tested of LE propofol and the longest of the 
exposure times chosen effectively changed cell proliferation. In detail, they 
resulted in an increase in cell proliferation rate when applied to primary canine 
tubular adenocarcinoma cells and in a decrease in cell proliferation when 
applied to metastatic tubular adenocarcinoma cells. Lipid-based propofol 
emulsion treatments effectively modified NET1 expression of canine 
mammary cancer cells. Both of the concentrations examined here induced a 
decrease in gene expression at most of the treatment time points, although 
increases in gene expression were also observed. Sevoflurane treatments 
modified cell proliferation rate in both cell lines, showing an increase or a 
decrease in cell proliferation when applied on CIPp or CIPm cells, respectively, 
compared with cells grown in the sole cell culture medium. The expression of 
NET1 increased only after the treatment with sevoflurane 4 mM in metastatic 
cells. 
 
6.1 Cell proliferation under propofol treatments (I) 
Lipid-based propofol emulsion treatments significantly modified cell 
proliferation rate of cultured canine tubular adenocarcinoma cells in a cell line-
dependent manner. Lipid-based propofol emulsion treatments significantly 
augmented and reduced cell proliferation in CIPp and CIPm cells, respectively, 
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compared with the control group. Time effects (i.e. 6 hours versus 12 hours of 
exposure) were also noticed, mainly in CIPm. 
Results on the effects of propofol on cancer cell growth from previous trials 
are controversial. For instance, propofol stimulated proliferation in gallbladder 
tumour cells (Zhang et al. 2012) and neuroblastoma cells (Wu et al. 2011), but 
decreased proliferation in osteosarcoma cells (Ye et al. 2014). Propofol has 
been advocated to prevent breast cancer cell proliferation in vitro, supporting 
the theory that it may reduce the incidence of cancer recurrence and prolong 
survival time in women with breast cancer (Siddiqui et al. 2005; Deegan et al. 
2009). 
In breast cancer cells, propofol at concentrations of 5 and 10 μg mL-1 
suppressed cell growth when applied to Michigan Cancer Foundation-7 (MCF-
7) oestrogen receptor-positive and on M.D. Anderson-Metastasis Breast-231 
(MDA-MB-231) oestrogen receptor-negative cell lines (Ecimovic et al. 2014). 
Propofol conjugates were able to significantly prevent cell growth when 
applied to MDA-MB-231 oestrogen receptor-negative breast cancer cells 
(Siddiqui et al. 2005), even though these effects were observed only with 
concentrations of approximately 20 μg mL-1 of propofol conjugates. In Study I, 
a decrease of absorbance was observed in CIPm cell lines treated with LE 
propofol for 12 hours at concentrations between 1 and 10 μg mL-1, which are 
considered to stay within the blood concentration levels achieved in dogs 
anaesthetized with propofol. In fact, whole blood propofol concentrations 
measured by Hughes and Nolan (1999) after administering 4 mg kg-1 of 
propofol followed by infusions of 0.2 - 0.4 mg kg-1 min-1 to 8 greyhounds 
ranged from 1.21 to 6.77 µg mL-1.  
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Unexpectedly, in the present study, a rise in cancer cell proliferation was 
noticed when applying LE propofol at nearly all concentrations and at both 
time points on CIPp. In a recent trial, also breast cancer cells (i.e. MDA-MB-
231) treated for 1, 4 and 12 hours with propofol (2 - 10 µg mL-1) exhibited an 
increase in proliferation rate in a dose- and time-dependent manner (Meng et 
al. 2017), with results appearing to disagree with those of Siddiqui et al. (2005) 
and Deegan et al. (2009). Meng and co-workers (2017) hypothesized that the 
augmented proliferation was partially connected with inhibition of the 
expression of p53, a gene involved in the suppression of cell mutation. This 
hypothesis is noteworthy considering that human and canine mammary 
tumours share molecular characteristics such as variations in the expression 
of steroid receptors (Chia et al. 2005) and mutations of suppressor gene p53 
(Morris et al. 2009). 
It is not well defined why LE propofol produced dissimilar effects in CIPp 
and CIPm cell lines in our study. A strong cell type dependency has not been 
described before. For instance, in a study by Ecimovic and co-workers (2014), 
propofol did not lessen proliferation of breast tumour cells at any of the studied 
concentrations (1 - 10 μg mL-1) or any of the exposure times (6, 12, 24, 36 
hours) in either oestrogen receptor-positive or oestrogen receptor-negative 
cell lines.  Therefore, an absence of propofol effect as well as an absence of 
dependency on dose, time and cell type were demonstrated. In Study II, a 
decrement in NET1 expression was detected when LE propofol was applied 
to CIPm. When LE propofol was applied to CIPp cells, a double effect on NET1 
expression was observed: increments of gene expression were noticed at 6 
and 48 hours and decrements of gene expression were noticed at 12 and 24 
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hours of exposure. Although the purpose of both tests (i.e. MTT and qPCR for 
NET1) was to evaluate possible propofol anti-cancer activities, the laboratory 
methods used were dissimilar, with one test assessing cell proliferation and 
the other assessing the expression of a gene linked to cell migration. Indeed, 
the ability to proliferate and the ability to migrate do not have to be the same 
in a particular cell evolutionary state or cell type and could be considerably 
diverse in primary and metastatic cells from the same tumour type (Martin et 
al. 2013).  
In this study, exposure times of 6 and 12 hours were used. The choice of 
these exposure times was based on previously reported studies published in 
human medicine in vitro (Ecimovic et al. 2013), with the aim of facilitating 
comprehensive comparisons between  studies.  
Different tests can be selected to evaluate cell proliferation. Hence, different 
outcomes between research trials may be the effect of dissimilar 
methodologies. In the present project, the MTT proliferation assay was chosen 
because it is one of the most commonly used techniques for the evaluation of 
mammary tumour response to drug exposure. The MTT assay is based on the 
quantification of absorbance, which is linked to variations in cell number (Tada 
et al. 1986). The reason why the cell number changes (e.g. augmentation or 
reduction in proliferation, cell death or apoptosis) cannot be determined with 
this method. Other trials, for instance, use techniques that associate the 
assessment of cell growth utilizing the Water Soluble Tetrazolium-1 assay and 
the evaluation of cellular viability and apoptosis utilizing a Vybrant apoptosis 
test kit (Siddiqui et al. 2005). 
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6.2 NET1 expression under propofol treatments (II) 
To the author’s knowledge, this is the first study to focus on the biological 
effects of a clinically available propofol formulation on NET1 expression in 
canine mammary cancer cell lines. We observed that both P1 and P10 
propofol concentrations induced a decrease in NET1 expression in CIPp after 
12 and 24 hours of exposure. In CIPm, only the higher concentration of 
propofol (i.e. P10) caused a reduction of NET1 expression after 6 and 12 hours 
of exposure. Paradoxically, an increased NET1 expression was observed in 
CIPp with both LE propofol concentrations and with the higher LE propofol 
concentration after 6 and 48 hours of exposure. To the author’s knowledge, 
this was the first time that such a divergent effect was described for a clinically 
available propofol formulation applied to a primary canine tumour cell line.  
As already stated, the NET1 protein is crucial for TGF1-induced 
cytoskeletal reorganization, N-cadherin expression and RhoA activation 
(Garcia-Mata et al. 2007). Being a RhoA-specific GEF, the NET1 protein plays 
an important role in the EMT, enabling tumour cells to invade and migrate 
(Clark et al. 2000). Silencing this gene has been previously associated with 
abolition of the inhibitory effect of propofol on the migrating ability of cancer 
cells (Ecimovic et al. 2014). Therefore, a reduction in NET1 expression may 
be interpreted as a potentially anti-metastatic effect. On the other hand, an 
increase of NET1 expression could be interpreted as an increased ability of 
the tumour cells to cause metastasis (Tu et al. 2010). Consistently, the co-
expression of NET1 protein and α6β4 integrin in the primary tumours of lymph 
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node-positive patients with invasive breast carcinoma was associated with 
decreased distant metastasis-free survival time (Gilcrease et al. 2009). 
In the present study, we chose cell lines originating from the same 
individual, but with different malignant potentials to compare the effects of 
propofol on primary and metastatic cells. The mRNA of NET1 was detectable 
in both CIPp and CIPm. However, NET1 protein showed a higher expression 
in CIPp than in CIPm. These findings suggest that CIPp has a higher 
invasiveness potential than CIPm. Indeed, it has been speculated that intrinsic 
mechanisms promoting cell invasion and migration are enhanced in CIPp due 
to the fact that this cell line is the one responsible for tumour dissemination to 
remote locations within the body (Uyama et al. 2006). Conversely, in CIPm, 
mechanisms responsible for cell migration may be attenuated thereby 
enabling these cells to adhere to each other and grow, establishing metastatic 
lesions in distant organs.  
The propofol doses reported in the present study were chosen to reflect the 
plasma concentrations obtained clinically during propofol anaesthesia in dogs 
(Hughes & Nolan 1999). A generic chemical form of propofol at concentrations 
between 1 and 10 µg mL-1 reduced NET1 expression by 49 - 79% in the MDA-
MB-231 oestrogen receptor-negative human breast adenocarcinoma cell line 
and by 42 - 88% in the MCF7 oestrogen and progesterone receptor-positive 
human breast adenocarcinoma cell line (Ecimovic et al. 2014). In contrast to 
our findings where NET1 expression was reduced in CIPm only with the higher 
concentration of LE propofol, Ecimovic and co-authors (2014) reported a lack 
of dose-dependent effect in MDA-MB-231 cells and MCF7 cells. Comparably, 
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in Study II both doses of LE propofol influenced NET1 expression and a dose-
dependent effect could not be demonstrated.  
Different results were found at different time points in Study II; however, the 
observed time effects did not follow a linear pattern. With the shorter exposure 
time (i.e. 6 hours) an increase of NET1 mRNA levels in CIPp was observed. 
This finding was unexpected and appears to indicate an enhancement of 
malignancy in primary tumour cells when exposed to LE propofol for that 
period of time. However, this effect was reversed after 12 and 24 hours of 
exposure, with LE propofol producing a reduction in gene expression in CIPp. 
Thereafter, a significant increase in NET1 expression was observed once 
again in CIPp. A time-dependent response in the expression of NET1 in CIPp 
when exposed to LE propofol could be advised in the light of these 
observations. Some sort of time dependency was already recognised in MDA-
MB-231 cells and MCF7 cells when it was noted that NET1 expression tended 
to return to baseline after incubation with LPA for 4 hours (Ecimovic et al. 
2014). However, the only significant change observed in CIPm was the 
reduction in NET1 expression. The present study does not provide enough 
elements for a comprehensive explanation of the phenomenon. 
It is unclear how the expression of the NET1 protein is modulated by 
propofol. In a previous study it was suggested that propofol modulates NET1 
by modifying the cellular microenvironment, rather than by a specific receptor 
pathway (Ecimovic et al. 2014). Other projects highlight the connection 
between TGF-β, microRNAs and NET1 expression as combined targets for 
propofol anti-metastatic activity (Shen et al. 2001; Kong et al. 2008; Lee et al. 
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2010; Ahmad et al. 2014), with, for instance, TGF-β increasing NET1 and 
mediating stress fibre formation in human keratinocytes (Shen et al. 2001).  
The possible anti-cancer properties of propofol have been previously 
reported in several studies. For instance, propofol provoked cancer cell 
apoptosis in human promyelocytic leukaemia HL-60 (Tsuchiya et al. 2002) and 
hepatic cancer cell HepG2 (Wei et al. 2017). Propofol promoted apoptosis in 
pancreatic cancer cells (i.e. MIA-PaCa-2) in a dose-dependent manner (Du et 
al. 2013). In human oesophageal squamous cell carcinoma (i.e. EC-1) 
propofol inhibited in vitro invasion and angiogenesis and induced apoptosis 
through regulation of S100A4 gene expression (Guo et al. 2015). In addition, 
propofol suppressed the EMT and consequently kidney fibrosis through TGF-
β/Smad3 signalling and regulation of miR-155 levels (Tsuchiya et al. 2002). In 
human MDA-MB-231 cells, propofol reduced cancer cell invasion via inhibition 
of nuclear factor kappa-light-chain-enhancer of activated B cell (NF-kB) 
pathway and subsequent reduction of matrix metalloproteinase 2 and matrix 
metallopeptidase 9 levels (Wei et al. 2017). Mammoto and colleagues (2002) 
showed that infusions of propofol at sub-anaesthetic doses for 4 weeks 
effectively inhibited pulmonary metastasis in mice inoculated with murine 
osteosarcoma cells suggesting its possible anti-invasive action in vivo.  
Paradoxically, propofol has also been linked with mechanisms that may 
enhance cancer development. In gallbladder cancer cells, propofol induced 
proliferation and promoted invasion in a dose- and time- dependent manner 
through the activation of nuclear factor erythroid-derived 2 (Nrf2; from Zhang 
et al. 2012). In another study, human breast cancer cells (i.e. MDA-MB-468) 
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exposed to propofol showed higher migratory potential compared to controls 
in a dose-dependent manner (Garib et al. 2002). 
 
6.3 Cell proliferation under sevoflurane treatments (III) 
Cellular proliferation rate was effectively modified in both cell lines after 
treatments with a commercially available sevoflurane formulation. However, 
the effects on the two examined cell lines were reversed. Indeed, we observed 
an increase in cell proliferation rate in CIPp cells, and in CIPm cells a decrease 
in cell proliferation rate.  
The MTT test is frequently used for the assessment of viable cell numbers. 
The test measures the conversion of MTT into purple formazan crystals, which 
are produced by the redox activity of living cells. A reduction in cellular redox 
activity indicates a decrement in cell viability or cell number, while an increase 
in cellular redox activity indicates an increment in cell viability or cell number. 
When studying cancer cells, an increase or decrease in cell number count can 
be interpreted as an increase or decrease in the cell proliferation rate (Van 
Meerloo et al. 2011). Therefore, in Study III it may be inferred that sevoflurane 
prevents the proliferation of CIPm, but enhances the proliferation of CIPp.  
Our study findings are not completely in agreement with the available 
scientific literature. Ecimovic and co-workers (2013) demonstrated that the 
exposure to sevoflurane for 6 hours at concentrations of 2, 3 and 4 mM 
amplified cell proliferation by 50 - 63% in metastatic oestrogen receptor-
positive human breast adenocarcinoma cells (MCF7 cell line) and by 50 - 67% 
in metastatic oestrogen receptor-negative human breast adenocarcinoma 
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cells (MDA-MB-231 cell line). Controversially, an anti-proliferative effect of 
sevoflurane at 2 mM was shown in C6 glioma cells (O’Leary et al. 2000). 
However, It should be considered that the C6 glioma cells derived from 
different tissues and were not in a tumour transformation state. Thus, possibly, 
underlines the role of cell type and cell evolutional phase, rather than other 
factors like concentration and contact time, on the ability to respond to drug 
exposure.  
Interestingly, the divergent response of CIPp and CIPm cells proliferation 
rates when exposed to sevoflurane is comparable to that shown when the 
same cell lines were exposed to the LE propofol formulation. Indeed, propofol 
exposure also induced an increase and a decrease in CIPp and CIPm cell 
proliferation rate, respectively. 
The choice of exposure times and concentrations in the present study was 
based on trials reported in human medicine in order to allow reasonable 
comparisons among studies (O’Leary et al. 2000; Ecimovic et al. 2013). 
However, based on sevoflurane molecular weight of 200.055 g/mol, 
concentrations between 1 and 4 mM correspond to concentrations of 0.2 - 0.8 
mg mL-1. These concentrations are actually 10 times higher than those 
observed in people undergoing elective cardiac surgery and receiving 
sevoflurane 1.8% inspiratory volume (Nitzschke et al. 2013). Considering that 
sevoflurane minimal alveolar concentration in dogs is only slightly higher than 
the one reported in humans (i.e. 2.10 - 2.36%; Kazama & Ikeda 1988; Scheller 
et al. 1990), we can assume that concentrations between 1 and 4 mM applied 
to cell cultures resembled plasma concentrations almost 10 times higher than 
those obtained in dogs anaesthetized with sevoflurane in clinical practice.   
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6.4 NET1 expression under sevoflurane treatments (III) 
The expression of NET1 was significantly increased only in CIPm cells treated 
with the highest concentration used (i.e. 4 mM) of a commercially available 
sevoflurane formulation. To the authors’ knowledge, this is the first study to 
investigate the effects of sevoflurane on the expression of NET1 gene 
expression. The NET1 plays a crucial role in cytoskeletal reorganization, N-
cadherin expression and RhoA activation (García-Mata et al. 2007; Lee et al. 
2010). Consequently, an increment in NET1 expression has been linked with 
more malignant cellular behaviours (Tu et al. 2010). Consistently, NET1 was 
demonstrated to be overexpressed in highly invasive cancer types such as 
human breast and gastric adenocarcinomas (Leyden et al. 2006). Expression 
of NET1 appears to be affected by some medications used in the perioperative 
period (Ecimovic et al. 2011; Ecimovic et al. 2014), as we observed also in 
Study II. In Study III, NET1 expression was only increased in CIPm after being 
exposed to the highest evaluated concentration of sevoflurane. This could be 
interpreted as sevoflurane enhancing the migration ability of CIPm.  
 
6.5 Study limitations 
6.5.1 In vitro study 
The in vitro nature of the current studies imposes some limitations (Ghallab 
2013). Initially, the mechanisms investigated are only small fragments of the 
wide and complex reality of cancer spread. In fact, numerous and intricate are 
the mechanisms that influence cancer recurrence. For instance, we cannot 
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exclude that propofol or sevoflurane influences cancer cells’ migration and 
proliferation by other means such as modulation of the immune system (Yuki 
et al. 2010) or upregulation of hypoxia-inducible stress factors. In addition, the 
concomitant effects of other agents administered during routine clinical 
practice could possibly interfere with the effects of propofol or sevoflurane 
observed on cancer cells in vitro. For instance, serum from patients with breast 
cancer who received general anaesthesia with sevoflurane and systemic 
opioids was applied to MDA-MB-231 breast cancer cells increasing both 
proliferation and migration of cancer cells compared with serum of patients 
who received propofol infusions and paravertebral blocks (Deegan et al. 
2009). Ultimately, it is difficult to extrapolate in vitro results to predict in vivo 
conditions. A large retrospective clinical study evaluated long-term survival of 
lung cancer patients undergoing volatile or intravenous anaesthesia for 
elective surgery. A statistically and clinically significant reduction in survival 
time was shown in patients receiving inhalational anaesthetics, including 
sevoflurane (Wigmore et al. 2016).  
Since Study I did not assess the molecular characteristics of the cultured 
cells, the reasons for CIPp and CIPm cell lines presenting dissimilar outcomes 
regarding proliferation when exposed to LE propofol could not be understood.  
On the same line, in the present study the expression of NET1 gene was 
investigated in canine mammary tumour cells without performing biological 
tests. Lipid-based propofol emulsion and sevoflurane clearly effectively 
influenced the expression of a gene closely related to increased cancer cell 
malignancy. However, any conclusion can be extended to the effects of LE 
propofol and sevoflurane on cellular behaviour. In particular, we believe it 
  Discussion 
   
 96 
would be beneficial to verify in future studies whether the expression of NET1 
is actually correlated with increased migration potential in canine mammary 
tumour cells and whether the reduction in NET1 expression caused by 
propofol effectively decreases cell migration. Finally, it would be expected that 
silencing NET1 in the presence of propofol would return the migration 
parameters to those obtained at baseline.  
 
6.5.2 Limitations in study design 
To perform propofol dilutions,  a clinically accessible propofol preparation 
including a lipid-based emulsion was utilized. This formulation is broadly 
utilized in veterinary anaesthesia and includes soybean oil, glycerol and egg 
lecithin as adjuvants. In a previous study in humans, the effects of an intralipid-
containing propofol formulation equivalent to the one described here were 
compared using a MTT assay with those of a propofol-free 10% intralipid 
emulsion on prostate cancer cell proliferation (Huang et al. 2014). No 
differences were observed between the control group and the group treated 
with the propofol-free 10% intralipid emulsion. No reports exist that assess the 
blood or plasma concentrations of the lipid emulsion constituents achieved 
after LE propofol administration in dogs. Unfortunately, a preliminary trial to 
asses these parameters was not considered during the present study design. 
Consequently, the introduction of a sham group treated with propofol-free lipid 
emulsion was disregarded in the present project for two reasons. First, it was 
unclear to the authors what concentration of the lipid emulsion should have 
been used to evaluate canine tumour cell proliferation in vitro. Second, there 
was evidence in human medicine indicating no changes between intralipid-
  Discussion 
   
 97 
containing propofol formulation and propofol-free 10% intralipid emulsion on 
cancer cell proliferation (Huang et al. 2014). However, we have to underline 
that the cell lines studied from Huang and colleagues were different from the 
ones studied in the present project. Therefore, these authors cannot fully state 
that the effects observed are completely due to propofol rather than to one or 
more of the constituents of the emulsion per se. 
In Study I, LE propofol was diluted with cell medium to 1, 5 or 10 μg mL-1 
while, in Study III, a clinically available sevoflurane formulation was diluted 
with cell medium to concentrations of 1, 2.5 or 4 mM. Dilutions of propofol and 
sevoflurane were performed by the same authors following instructions in 
papers from Ecimovic and colleagues in 2014 and 2013, respectively. 
However, a subsequent verification of obtained concentrations was not 
performed. Following these considerations, the authors cannot state to exactly 
know which drug concentrations were applied on cell culture. 
In Study III, we utilized concentrations of Sevoflurane between 1 and 4 mM. 
Originally, the choice of these concentrations was done to allow comparisons 
with the study of Ecimovic and co-workers (2013) where sevoflurane was 
applied on breast cancer cells to asses proliferation, migration and invasion. 
These concentrations resulted to correspond to concentrations 10 times 
higher than those reported by Nitzschke and colleagues (2013) in people 
exposed to sevoflurane 1.8% inspiratory volume. Consequently, the present 
authors can only describe the effect of the investigated concentrations of 
sevoflurane. A statement regarding the effects of clinically used sevoflurane 
concentrations on cancer cell behaviour cannot be made.  
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During statistical analysis, we did not perform any test for multiple 
comparisons correction. With the significance level of p < α = 0.05 chosen for 
the present project, it is possible to gauge from figures showing means plus 
minus the standard error if two conditions differ significantly by the lack of 
overlap between pairs of conditions. For this reason, tests for the correction 
for multiple comparisons were considered not necessary. However, we cannot 
exclude we could have observed slightly different results if a test for multiple 
comparisons correction would have been applied. 
 
6.6 Practical relevance and future perspectives 
In recent years, several in vitro studies have been focusing on the effects of 
anaesthetics on cancer recurrence (Melamed et al. 2003; Siddiqui et al. 2005; 
Deegan et al. 2009; Wada et al. 2007; Ecimovic et al. 2013; Ecimovic 2014; 
Song et al. 2014; Ye et al. 2014). However, the much more complex setting in 
the clinical practice renders challenging a direct translation of information from 
in vitro to in vivo scenarios. Actually, an advantage of propofol over inhalant 
anaesthetics when anaesthetising cancer patients for surgical cancer removal 
has been demonstrated by few retrospective clinical trials in human medicine 
(Buckley et al 2014; Wigmore et al. 2016). Conversely, data from in vitro trials 
are not entirely in agreement.  
It is these authors’ opinion that many are nowadays the unanswered 
questions regarding the relationship between cancer recurrence and 
anaesthetics, in particular when speaking about veterinary medicine.  
  Discussion 
   
 99 
Starting from the results and limits of the present study, several further 
investigations can be suggested. The role of intralipid emulsion on canine 
cancer cell should be examined to better understand whether changes in cell 
behaviour when applying intralipid-containing propofol formulations are due to 
propofol molecules per se or not. Different cell lines could be utilized to 
analyse canine cancer cell response to propofol and sevoflurane, since we 
cannot exclude different reactions between different cell lines. More research 
should be performed on other aspects of cancer cell behaviour such as 
invasion, migration and the expression of oncogene others than NET1. Finally, 
it would be interesting to study a wider range of concentrations of propofol and 
sevoflurane compared with those here reported.  
During the time spent in reading about the topic of this dissertation, the 
authors found fascinating the amount of information available in human 
medicine regarding the possible effects of drugs others than propofol and 
sevoflurane on cancer recurrence. Indeed, we would consider beneficial a 
deep investigation on the role of opioids and local anaesthetics on cancer 
recurrence. 
Not only for the potential benefits of canine patients, but also due to recent 
recognition of canine mammary tumours as possible translational models of 
naturally occurring breast cancer in people (Alvarez 2014), the authors 
advocate clinical veterinary trials on canine patients affected with mammary 
tumours to achieve a wider understanding of the influence of anaesthetic 
techniques on cancer recurrence. Ideally, we would suggest the development 
of prospective randomised blinded clinical trials involving canine females 
affected with mammary cancer. The aim would be to compare the metastasis-
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free time after surgery between canine patients anaesthetized with propofol or 
sevoflurane and receiving an opioid-based or a local anaesthetic-based 
analgesia. The goal would be to identify which anaesthetic protocol results in 
the longer metastasis-free time after surgery.   





1. Exposure to LE propofol significantly influenced canine mammary tumour 
cell proliferation rate. Higher but still clinically relevant concentrations of 
LE propofol and longer exposure times resulted in a significant increase 
in cell proliferation when applied to primary canine mammary tumour cells 
and a significant decrease in cell proliferation when applied to metastatic 
canine mammary tumour cells (Study I). 
2. Exposure to LE propofol significantly influenced canine mammary tumour 
cell NET1 expression. Both examined concentrations induced a significant 
decrease in gene expression at most of the treatment time points, 
although increases in gene expression were also observed (Study II). 
3. Exposure to sevoflurane significantly influenced canine mammary tumour 
cell proliferation rate. Significant increases or decreases of cell 
proliferation rate were observed when sevoflurane was applied to primary 
or metastatic canine mammary tumour cells, respectively, compared with 
cells grown solely in the cell culture medium (Study III). 
4. Exposure to sevoflurane significantly influenced canine mammary tumour 
cell NET1 expression, but only when the higher concentration of 
sevoflurane was applied to the metastatic canine mammary tumour cells 
(Study III). 
Further studies, including biological tests, gene silencing and clinical trials, are 
warranted to elucidate the role of anaesthetic techniques in cancer recurrence.  
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